

BRD: WB/IL-1

March 2006

**THE HUMAN WHOLE BLOOD/IL-1  
IN VITRO PYROGEN TEST  
(WB/IL-1)**

BRD: WB/IL-1

March, 2006

**Contents**

1 RATIONALE FOR THE PROPOSED TEST METHOD..... 4

    1.1 INTRODUCTION.....4

    1.2 REGULATORY RATIONALE AND APPLICABILITY .....5

    1.3 SCIENTIFIC BASIS FOR THE PROPOSED TEST METHOD .....6

2 TEST METHOD PROTOCOL COMPONENTS ..... 8

    2.1 OVERVIEW OF TEST METHOD.....8

    2.2 RATIONAL FOR SELECTED TEST COMPONENTS .....9

    2.3 BASIS FOR SELECTION OF THIS TEST METHOD.....13

    2.4 PROPRIETARY COMPONENTS .....13

    2.5 REPLICATES.....14

    2.6 MODIFICATIONS APPLIED AFTER VALIDATION.....14

    2.7 DIFFERENCES WITH SIMILAR TEST METHODS.....14

3 SUBSTANCES USED FOR VALIDATION ..... 15

    3.1 SELECTION OF SUBSTANCES USED.....15

    3.2 NUMBER OF SUBSTANCES .....15

    3.3 DESCRIPTION OF SUBSTANCES USED .....16

    3.4 SAMPLE CODING PROCEDURE .....17

    3.5 RECOMMENDED REFERENCE CHEMICALS .....17

4 *IN VIVO* REFERENCE DATA ON ACCURACY ..... 18

    4.1 TEST PROTOCOL *IN VIVO* REFERENCE TEST METHOD.....18

    4.2 ACCURACY .....18

    4.3 ORIGINAL RECORDS .....19

    4.4 QUALITY OF DATA .....19

    4.5 TOXICOLOGY .....20

    4.6 BACKGROUND ON ASSAY PERFORMANCE .....20

5 TEST METHOD DATA AND RESULTS ..... 21

    5.1 TEST METHOD PROTOCOL .....21

    5.2 ACCURACY AND RELIABILITY .....23

    5.3 STATISTICS .....29

    5.4 TABULATED RESULTS .....32

    5.5 CODING OF DATA .....34

    5.6 CIRCUMSTANCES.....34

    5.7 OTHER DATA AVAILABLE .....34

6 TEST METHOD ACCURACY ..... 35

    6.1 ACCURACY .....35

    6.2 CONCORDANCY TO *IN VIVO* REFERENCE METHOD.....37

    6.3 COMPARISON WITH REFERENCE METHODS .....37

    6.4 STRENGTH AND LIMITATIONS.....37

    6.5 DATA INTERPRETATION .....38

    6.6 COMPARISON TO OTHER METHODS .....38

7 TEST METHOD RELIABILITY (REPEATABILITY/REPRODUCIBILITY)..... 39

    7.1 SELECTION OF SUBSTANCES .....39

    7.2 RESULTS .....39

    7.3 HISTORICAL DATA.....44

    7.4 COMPARISON TO OTHER METHODS .....44

8 TEST METHOD DATA QUALITY ..... 45

BRD: WB/IL-1

March, 2006

8.1	CONFORMITY .....	45
8.2	AUDITS .....	45
8.3	DEVIATIONS .....	45
8.4	RAW DATA.....	45
9	OTHER SCIENTIFIC REPORTS AND REVIEWS.....	46
9.1	SUMMARY .....	46
9.2	DISCUSSION.....	47
9.3	RESULTS OF SIMILAR VALIDATED METHOD .....	48
10	ANIMAL WELFARE CONSIDERATIONS (REFINEMENT, REDUCTION, AND REPLACEMENT) .....	51
10.1	DIMINISH ANIMAL USE.....	51
10.2	CONTINUATION OF ANIMAL USE.....	51
11	PRACTICAL CONSIDERATIONS.....	53
11.1	TRANSFERABILITY .....	53
11.2	TRAINING .....	53
11.3	COST CONSIDERATIONS.....	54
11.4	TIME CONSIDERATIONS .....	54
12	REFERENCES.....	55
13	CATCH-UP VALIDATION: HUMAN WB/IL-1 IN VITRO PYROGEN TEST USING 96-WELLS PLATES.....	57
13.1	RATIONALE .....	57
13.2	TEST METHOD PROTOCOL COMPONENTS.....	57
13.3	SUBSTANCES USED FOR VALIDATION.....	57
13.4	PRELIMINARY ESTIMATE OF THE TEST METHOD ACCURACY .....	57
13.5	TEST METHOD ACCURACY .....	61
13.6	TEST METHOD RELIABILITY (REPRODUCIBILITY).....	65
13.7	CONCLUSION .....	65
14	SUPPORTING MATERIALS (APPENDICES) .....	66
14.1	STANDARD OPERATING PROCEDURE (SOP) OF THE PROPOSED METHOD .....	66
14.2	STANDARD OPERATING PROCEDURE (SOP) OF THE REFERENCE METHOD.....	66
14.3	PUBLICATIONS.....	66
14.4	ORIGINAL DATA .....	71
14.5	PERFORMANCE STANDARDS .....	72

Appendix A – Method protocol(s) and trial plan(s)

Appendix B – Hardcopies of relevant publications

Appendix C – List of abbreviations and definitions

BRD: WB/IL-1

March, 2006

## 1 Rationale for the Proposed Test Method

### 1.1 Introduction

1.1.1. Describe the historical background for the proposed test method, from original concept to present. This should include the rationale for its development, an overview of prior development and validation activities, and, if applicable, the extent to which the proposed test method is mechanistically and functionally similar to a validated test method with established performance standards.

Pyrogens, a chemically heterogeneous group of hyperthermia- or fever-inducing compounds, derive from bacteria, viruses, fungi. Subjects react to such microbial products during an immune response by producing endogenous pyrogens such as prostaglandins and the pro-inflammatory cytokines interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) (Dinarello, 1999). Depending on the type and amount of pyrogen challenge and the sensitivity of an individual, even life-threatening shock-like conditions can be provoked. To assure quality and safety of any pharmaceutical product for parenteral application in humans, pyrogen testing is therefore imperative.

Depending on the medicinal product, one of two animal-based pyrogen tests is currently prescribed by the respective Pharmacopoeias, i.e. the rabbit pyrogen test and the bacterial endotoxin test (BET). For the rabbit pyrogen test, sterile test substances are injected intravenously to rabbits and any rise in body temperature is assessed. This *in vivo* test detects various pyrogens but not alone the fact that large numbers of animals are required to identify a few batches of pyrogen-containing samples argues against its use. In the past two decades, the declared intention to refine, reduce and replace animal testing, has lowered rabbit pyrogen testing by 80% by allowing to use the BET as an *in vitro* alternative pyrogen test for certain medicinal products (Cooper et al, 1971).

Bacterial endotoxin, comprising largely lipopolysaccharide (LPS) from the cell wall of Gram-negative bacteria that stimulates monocytes/macrophages via interaction with CD14 and toll-like receptor 4 (TLR4) (Beutler and Rietschel, 2003), is the pyrogen of major concern to the pharmaceutical industry due to its ubiquitous sources, its stability and its high pyrogenicity. With the BET, endotoxin is detected by its capacity to coagulate the amoebocyte lysate from the haemolymph of the American horseshoe crab, *Limulus polyphemus*, a principle recognised some 40 years ago (Levin and Bang, 1964). In the US, *Limulus* crabs are generally released into nature after drawing about 20% of their blood and therefore most of these animals survive. However, the procedure still causes mortality of about 30,000 horseshoe crabs per year, which adds to even more efficient threats of the horseshoe crab population like its use as bait for fisheries, habitat loss and pollution (<http://www.horseshoecrab.org/>).

As with the rabbit test the general problem of translation of the test results to the human fever reaction persists. Moreover, although being highly sensitive, the failure of the BET to detect non-endotoxin pyrogens as well as its susceptibility to interference by e.g. high protein or lipid levels of test substances or by glucans impedes full replacement of the rabbit pyrogen test. Hence, hundreds-of-thousands rabbits per year are still used for pyrogen testing.

BRD: WB/IL-1

March, 2006

A test system that combines the high sensitivity and *in vitro* performance of the BET test with the wide range of pyrogens detectable by the rabbit pyrogen test is therefore required in order to close the current testing gap for pyrogen and to avoid animal-based tests. With this intention and due to improved understanding of the human fever reaction (Dinarelo, 1999), test systems based on *in vitro* activation of human monocytes were developed. First efforts date back about 20 years, when peripheral blood mononuclear cells (PBMC) were used to detect endotoxin by monitoring the release of pyrogenic cytokines (Duff and Atkins, 1982; Dinarelo et al 1984). Meanwhile, a number of different test systems, using either whole blood, peripheral blood mononuclear cells (PBMCs) or the monocytoïd cell lines MONO MAC 6 (MM6) or THP-1 as a source for human monocytes and various read-outs were established (Poole et al., 1988; Ziegler et al, 1988; Tsuchiya et al, 1980; Hartung and Wendel, 1996; Hartung et al, 2001; Poole et al, 2003). These test systems were validated with the aim of developing a tool for formal inclusion into Pharmacopoeias, an important basis for implementing novel alternative pyrogen tests for product-specific validation.

1.1.2 *Summarize and provide the results of any peer review conducted to date and summarize any ongoing or planned reviews.*

All of the five methods are currently under peer review of the ECVAM Scientific Advisory Committee.

1.1.3 *Clearly indicate any confidential information associated with the test method; however, the inclusion of confidential information is discouraged.*

This document does not contain any confidential information.

## **1.2 Regulatory rationale and applicability**

1.2.1 *Describe the current regulatory testing requirement(s) for which the proposed test method is applicable.*

To assure quality and safety of pharmaceutical products for parenteral application in humans, pyrogen testing is imperative. Depending on the drug, one of two pyrogen tests is currently prescribed by the European Pharmacopoeia and other international guidelines, i.e. the rabbit pyrogen test and the bacterial endotoxin test (BET).

1.2.2 *Describe the intended regulatory use(s) (e.g., screen, substitute, replacement, or adjunct) of the proposed test method and how it will be used to substitute, replace, or complement any existing regulatory testing requirement(s).*

Dependent on the product and the presence of relevant clinical data on unexpected pyrogenicity of clinical lots, the proposed test method may be an alternative method for pyrogen testing, thus substituting the rabbit pyrogen test or the BET. In certain cases, the proposed test method may function as a supplementary test method to assess compliance to the licensing dossier.

In case the proposed test method is an alternative for pyrogenicity testing, a thorough cross-validation between the proposed test method and the original method for the specific medicinal product is warranted. In case the proposed test method is an adjunctive test to screen for (unexpected) pyrogenic lots, alert and alarm limits may be established based on consistency of production lots or (preferably) based on actual clinical data.

BRD: WB/IL-1

March, 2006

1.2.3 *Where applicable, discuss the similarities and differences in the endpoint measured in the proposed test method and the currently used in vivo reference test method and, if appropriate, between the proposed test method and a comparable validated test method with established performance standards.*

The current *in vivo* method (rabbit test), as described in the pharmacopoeia, and the proposed *in vitro* test method each determine very different end-points, though the biochemical origins of the response are similar.

The *in vivo* method more resembles a black box, and determines the total rise in body temperature (fever induction) of the animals subjected to the medicinal product, as a result of pyrogens (if any) present in the product.

The proposed test method WB/IL-1 is an *in vitro* model for the fever response mechanism. It determines the release of cytokines by monocytoïd cells into the culture medium upon the interaction of pyrogens and specific receptors on the monocytoïd cells. It is these cytokines that trigger the fever response *in vivo*.

Main differences between the *in vivo* and *in vitro* methods are that the latter is quantitative and uses cells of human origin, thus better reflecting the physiological situation.

1.2.4 *Describe how the proposed test method fits into the overall strategy of hazard or safety assessment. If a component of a tiered assessment process, indicate the weight that should be applied relative to other measures.*

The proposed test method WB/IL-1 may be applied for those medicinal products for which the rabbit test is the only or most reliable method for pyrogenicity testing, since a) the medicinal product is not compatible with the BET or b) the medicinal product contains pyrogens other than Gram-negative endotoxin.

Limit concentrations for pyrogens are established based on consistency lots or actual clinical data or, in the case of endotoxin the Endotoxin Limit Concentration (ELC) as defined for many medicinal products.

### 1.3 Scientific basis for the proposed test method

1.3.1 *Describe the purpose and mechanistic basis of the proposed test method.*

The proposed *in vitro* method is intended to determine the presence of pyrogens in medicinal products for parenteral use. The proposed test method is an *in vitro* model of the human fever response. It determines the release of cytokines upon the interaction of pyrogens and specific Toll-like receptors on the monocytoïd cells (Beutler and Rietschel, 2003). These cytokines trigger the fever response *in vivo*.

1.3.2 *Describe what is known and not known about the similarities and differences of modes and mechanisms of action in the proposed test method as compared to the species of interest (e.g., humans for human health-related toxicity testing).*

An important feature of the proposed test method is that it is based upon the use of monocytoïd cells of human origin. It therefore by definition resembles more closely the actual response of humans. The two other test methods make use of either crustaceans (BET) or rabbits, both species more or less distinct from the human species. The response of humans, horseshoe crabs and rabbits toward Gram-negative endotoxin has been

BRD: WB/IL-1

March, 2006

studied extensively and the methods appear equivalent for this particular pyrogen (Cooper et al 1971; Greisman and Hornick, 1969). However, there are documented cases of medicinal products and specified pyrogenic substances that yield false-positive or false-negative results in either test method. Since the proposed test method is based on human cells, it may therefore predict more accurately the pyrogenicity of such substances in humans.

*1.3.3 Describe the intended range of substances amenable to the proposed test method and/or the limits of the proposed test method according to chemical class or physicochemical factors.*

The proposed test method is intended for the assessment of pyrogens in all parenteral medicinal products for human use, chemical or biological and including raw materials, bulk ingredients and excipients. Use of the proposed test method in testing environmental samples or medicinal products is suggested and may be feasible, but substantiating data are as yet limited or absent.

BRD: WB/IL-1

March, 2006

## 2 Test Method Protocol Components

### 2.1 Overview of test method.

*Provide an overview of how the proposed test method is conducted. If appropriate, this would include the extent to which the protocol for the proposed test method adheres to established performance standards.*

A highly detailed protocol of the proposed test method (*Detailed protocol WB/IL-1: "Human whole blood pyrogen test"; electronic file name: SOP WB-IL-1*) is attached in Appendix A of this background review document (BRD). Appendix A also includes the amended protocol used in the formal validation study to determine the sensitivity and specificity of the test (section 3, table 3.3.1). However, it does only replace the previous version for testing of parenteral drugs described in table 3.3.1, and was included into Appendix A for completeness of information only (*"Human Whole Blood Pyrogen Test - Standard Operating Procedure for the Validation Phase" marked with internal identifier Sop-WBT-KNv02; electronic file name: SOP WB-IL-1 validation*).

The WB/IL-1 test method is a two-part assay for the detection of pyrogenic contamination. The test protocol itself can be divided into the following two parts:

1. Incubation of the sample with (diluted) human blood.
2. An enzyme linked immunoassay (ELISA) for the measurement of IL-1 $\beta$ .

#### Ad 1.

Human whole blood from a single healthy volunteer is collected by venipuncture into heparinized tubes for blood sampling and used within 4 hours. Diluted human whole blood is incubated overnight (10-24 hours) together with saline and the sample of interest in sterile and pyrogen-free reaction tube. The supernatant is subsequently collected for further examination.

#### Ad 2.

Samples (supernatants of blood stimulation) are distributed into the wells of a microtiterplate which are coated with monoclonal antibodies specific for IL-1. An enzyme-conjugated polyclonal antibody against IL-1 $\beta$  is added. During a 90-minute incubation, a sandwich complex consisting of two antibodies and the IL-1 $\beta$  is formed. Unbound material is removed by a wash step. A chromogenic substrate (3,3',5,5' -tetramethylbenzidine, TMB) reactive with the enzyme label is added. Color development is terminated by adding a stop solution after 30 minutes. The resulting color, read at 450 nm, is directly related to the IL-1 $\beta$  concentration.

The WHO-LPS standard (code 94/580, E.coli O113:H10:K-), was used throughout the validation. This standard is identical to USP Reference Standard Endotoxin (EC6). There are several possibilities to estimate the pyrogenic contamination of the preparations under test: 1) A quantitative estimation can be achieved by the construction of a dose-response curve for endotoxin standard (e.g. 5.0, 2.5, 1.0, 0.5 and 0.25 EU/ml) versus



BRD: WB/IL-1

March, 2006

Optical density (OD) value of the IL-1 $\beta$  ELISA. The contamination of the preparations is expressed in endotoxin–equivalent units. 2) A qualitative test can be achieved by the inclusion of an endotoxin threshold control (e.g. one fixed dilution of the standard curve) which allows for the classification in positive and negative samples (i.e. pyrogenic and non-pyrogenic samples). 3) A qualitative test can also be achieved by inclusion of an appropriate positive product control.

A detailed description of analysis methods used during the validation of the test method can be found in section 5 of the current BRD.

## 2.2 Rational for selected test components

*Provide a detailed description and rationale, if appropriate, for the following aspects of the proposed test method:*

### 2.2.1 Materials, equipment, and supplies needed.

The materials, equipment and supplies used for the WB/IL-1 test method are laboratory items, that will be already available in a routine QC laboratory. There is no need for sophisticated or dedicated laboratory equipment throughout the test.

For all steps in the procedure, excluding the ELISA procedure, the materials (e.g. tips, containers, solutions) which will be in close contact with samples and blood cells need to be sterile and pyrogen free. The materials, equipment and supplies are specified in the detailed protocol attached in Appendix A. It should be noted that equivalent devices may also be used and it is the user's responsibility to validate the equivalence.

#### Materials for part 1: Blood Incubation

##### Equipment

- Incubator or thermoblock (37°C  $\pm$  1°C)
- Adjustable 100 to 1000  $\mu$ l (multi)pipettes
- Centrifuge (recommended)
- Vortex mixer

##### Consumables

- Heparinized tubes for blood sampling, e.g. Sarstedt S-MONOVETTE 7.5 ml, 15 IU/ml Li-Heparin
- Sarstedt multifly needle set, pyrogenfree, for S-Monovette
- 1.5 ml closable, pyrogen-free reaction tubes, e.g. from Eppendorf
- Reservoir for saline
- 12 ml or 15 ml tubes, e.g. from Greiner bio-one, for dilution of substances
- Sterile and pyrogen-free tips 100  $\mu$ l and 1000  $\mu$ l
- 10 ml and 2.5 ml pipets

#### Materials for part 2: ELISA procedure

##### Equipment

- Multichannel pipettor
- Microplate mixer
- Microplate washer
- Microplate reader capable of readings at 450 nm (optional reference filter in the range of 600-690 nm)

BRD: WB/IL-1

March, 2006

- A software package facilitating data generation, analysis, reporting, and quality control

#### Consumables

- Graduated cylinder and plastic storage container for Buffered Wash Solution
- Tip-Tubs for reagent aspiration with Multichannel pipettor
- The IL-1 $\beta$ -ELISA kit (commercially obtained), containing:
  - IL-1 $\beta$  antibody coated micropates.
  - Enzyme labeled antibody. Horseradish peroxidase-labeled, affinity-purified, polyclonal(rabbit) anti-IL-1 $\beta$  antibodies.
  - Endotoxin control.
  - Saline
  - TMB/Substrate solution
  - Buffered Wash Solution Concentrate (saline solution, with surfactants and preservative)
  - Stop Solution (acidic solution)

#### 2.2.2 Dose-selection procedures, including the need for any dose range-finding studies or acute toxicity data prior to conducting a study, if applicable.

For every kind of test compound the interference with human blood and the IL-1 $\beta$  ELISA kit is determined. For this purpose, a preliminary “dose finding” test is conducted to establish a suitable (interference free) dilution for every new test compound. For the validation study (as described in section 4 of this BRD), the tested products were diluted according to their known ELC, which was usually far beyond interfering concentrations. The ELCs of the tested products or drugs were calculated according to the European Pharmacopoeia.

#### 2.2.3 Endpoint(s) measured.

The proposed test method is an *in vitro* model of the fever response mechanism. It determines the release of interleukin-1 $\beta$  (IL-1 $\beta$ ) by monocytoïd cells present in human blood. IL-1 $\beta$  is released into the culture medium upon the interaction of pyrogens and specific receptors on the monocytoïd cells. The measured endpoint IL-1 $\beta$  is one of the cytokines that trigger the fever response *in vivo*.

#### 2.2.4 Duration of exposure.

The human whole blood is exposed to possible pyrogenic components in samples overnight (10-24 hours) at 37°C. During the validation (described in section 4) the exposure of the cells was discontinued by centrifugation (2 minutes at 10,000 g) and collection of the clear supernatant. This supernatant, containing endogenous pyrogens released by the cells, is subsequently assayed in the IL-1 $\beta$  ELISA.

#### 2.2.5 Known limits of use.

The WB/IL-1 method described in the method protocol is not a finalized test system for the testing of all medicinal products. The method may be applied only to preparations that have been validated with this method, i.e. shown not to interfere with the blood and the IL-1 $\beta$  readout system at a specified dilution of the preparation. A paragraph describing the interference testing is included in the method protocol (see Appendix A).

IL-1 $\beta$  readout system at a specified dilution of the preparation. A paragraph describing the interference testing is included in the method protocol (see Appendix A). However, at this moment there are no medicinal products known that cannot be tested with the method.

#### *2.2.6 Nature of the response assessed.*

The proposed test method is an *in vitro* model of the fever response mechanism. Upon the interaction of exogenous pyrogens and specific receptors on the monocytoïd cells endogenous pyrogens (e.g. interleukins, TNF- $\alpha$  and prostaglandins) are produced. In the body the fever response is triggered by these endogenous pyrogens. Immunoreactive IL-1 $\beta$ , the measured endpoint for the current method, is one of these endogenous pyrogens.

#### *2.2.7 Appropriate vehicle, positive, and negative controls and the basis for their selection.*

Throughout the development and validation phase the test compounds are diluted in 0.9% (w/v) clinical saline. This 0.9% clinical saline is considered an appropriate vehicle as no interference with active substances of a drug is to be expected.

In addition the test includes several controls.

A negative control: 0.9% clinical saline (sodium chloride)

A positive control: WHO-LPS 94/580, 0.5 EU/ml in clinical saline.

A negative product control: clean, released batch for each drug.

A positive product control: test item spike with WHO-LPS (code 94/580) at 0.5 EU/ml

The positive and negative controls are the same in every assay and are needed to establish the sensitivity of the test system. In addition, a product-based set of controls is used to reveal product-related interference.

#### *2.2.8 Acceptable range of vehicle, positive and negative control responses and the basis for the acceptable ranges.*

A WB/IL-1 assay is considered acceptable for further analysis if the mean OD of the positive control (0.5 EU/ml) exhibits an OD that is greater than 1.6 times the mean OD over the negative control (0.9% clinical saline). Moreover the response to different concentrations of the positive control should show a dose response relationship. To be able to quantify the responses to the positive control this should be well within the maximum response that can be measured with the test system.

As regards the substances to be tested, for products with an established ELC (specified in EU/ml), the product is diluted to its maximum valid dilution (MVD). The negative product control should be negative at the MVD. The response to the positive product control should be between 50% and 200% of the response to the positive control, indicating a possible pyrogenicity can be detected using these conditions.

#### *2.2.9 Nature of the data to be collected and the methods used for data collection.*

The raw data collected are the read-outs (absorbance) of the IL-1 $\beta$  ELISA, measured by an automated laboratory ELISA-plate reader. The wavelength is dependent on the chromogenic substrate applied, but when using TMB, the ELISA-plate is read at a

BRD: WB/IL-1

March, 2006

*2.2.10 Type of media in which data are stored.*

Data are stored in electronic files (windows98 compatible software) and as hard copy.

*2.2.11 Measures of variability.*

As part of the development of the WB/IL-1 test method the intralaboratory repeatability was assessed by independent and identical replicated measurement of the different concentrations of WHO-LPS. Furthermore, the limit of detection and its dependence from known but uncontrollable variables such as operator and passage of the cell line were investigated. These variables and the inherent variation of biological systems make up to the total variation of the method.

*2.2.12 Statistical or nonstatistical methods used to analyze the resulting data, including methods to analyze for a dose-response relationship. Justify and describe the method(s) employed.*

All experiments are run with four replicates of the test compound with blood from one donor on one plate. A standard curve in quadruplicate, using the International Standard for endotoxin (calibrated in EU) is included, ranging from 0.25 EU/ml up to 2.5 EU/ml. Outliers are rejected only after checking according to the Grubbs test, and applied to identify and eliminate aberrant data. Next, the negative and the respective positive control are compared to ensure a suitable limit of detection, which should be  $>0.25$  EU/ml. The mean OD of the 0.5 EU/ml endotoxin control exhibits an OD that is greater than 1.6x the OD of the negative saline control.

*2.2.13 Decision criteria and the basis for the prediction model used to classify a test chemical (e.g., positive, negative, or equivocal), as appropriate.*

A prediction model (PM) was developed in order to classify substances as “pyrogenic for humans” or “non-pyrogenic for humans”. To be able to define a dichotome result in the alternative pyrogen test, a threshold pyrogen value of 0.5 EU/ml was chosen. This threshold value was based on historical data with rabbits (described in section 4.1). The suitability of the PM was assessed by testing substances which were artificially contaminated with endotoxin (substances are described in section 3.2 and 3.3). The statistical approach, including quality criteria, is detailed in section 5.3

*2.2.14 Information and data that will be included in the study report and availability of standard forms for data collection and submission.*

Raw data were collected using a standard form. These were submitted to the quality department of ECVAM.

### 2.3 Basis for selection of this test method

*Explain the basis for selection of the test method system. If an animal model is being used, this should include the rationale for selecting the species, strain or stock, sex, acceptable age range, diet, and other applicable parameters.*

In view of the shortcomings of the rabbit pyrogen test and the BET, *in vitro* pyrogen tests that utilize the exquisite sensitivity to exogenous pyrogen of monocytoid cells have been proposed. In such tests, products are incubated with human cell and the conditioned media assayed for pyrogenic cytokines (Duff & Atkins, 1982; Dinarello et al., 1984; Poole et al., 1988; Poole et al., 1989; Hansen and Christensen, 1990; Taktak et al., 1991; Bleeker et al., 1994).

The human whole blood assay was developed as a real *in vitro* alternative to the rabbit pyrogen test. The basic idea was to mimic the fever reaction in humans. In general, the detection of exogenous pyrogens (e.g. endotoxin) by blood cells causes them to release endogenous pyrogens like IL-1 $\beta$ , IL-6 and TNF  $\alpha$ . These cytokines affect the thermal regulation centre in the brain and increase the body temperature by changing its set point. In the past several test methods have been developed that use the sensitivity of human peripheral blood monocytes to exogenous pyrogens. In an attempt to increase the sensitivity of these tests the monocytes/leukocytes were isolated from whole blood. In addition, various cell lines, which retain monocytoid characteristics, including the capacity to synthesize and secrete pyrogenic cytokines, have been studied.

However, the isolation of monocytes/leukocytes from whole blood as well as the maintenance of a cell-line is labour-intensive and time-consuming, technically sophisticated and requires expensive reagents. It is clear that using whole blood implies considerably simplified handling and that costs are limited. In an early stage of development of the assay, interleukin-1 $\beta$  was most promising as the endogenous pyrogen used as the readout. In addition, a standardised version of the test in form of an interleukin-1 $\beta$  kit is commercially available.

### 2.4 Proprietary components

*If the test method employs proprietary components, describe what procedures are used to ensure their integrity (in terms of reliability and accuracy) from "lot-to-lot" and over time. Also describe procedures that the user may employ to verify the integrity of the proprietary components.*

T. Hartung and A. Wendel are named as inventors in Patent Number US 5,891,728, Apr 6, 1999: 'Test for determining pyrogenic effect of a material'.

It is stated in the method protocol that components supplied in the ELISA kit are not interchangeable with other lots of the same components. Including the appropriate positive and negative controls in each run ensures the reliability and accuracy of the WB/IL-1 test method. As a positive control a specified amount of the Endotoxin Standard is used. The assay should be considered acceptable only if the following criteria are met: The mean absorbance of the 0.5 EU/ml endotoxin control exhibits a value is greater than 1.6x the mean absorbance of the negative saline control. Requirements are set for variability of replicates within an assay.

In addition the response to the negative control should be well below limit of detection.

BRD: WB/IL-1

March, 2006

## 2.5 Replicates

*Describe the basis for the number of replicate and repeat experiments; provide the rationale if experiments are not replicated or repeated.*

All experiments are run with four replicates of the test compound on one plate. Outliers are rejected only after checking according to the Grubbs test ( $p > 0.05$ ). Four replicates is considered the minimal amount for the Grubbs test.

During a prevalidation phase, the intralaboratory reproducibility as well as the interlaboratory reproducibility of the WB/IL-1 test method was established by applying repeated experiments (see section 7). As the test method reliability (repeatability /reproducibility) was shown to be satisfactory, it was feasible to establish the accuracy using pharmaceutical substances (detailed in table 3.3.1) by one test performed by three participating laboratories (see section 6).

## 2.6 Modifications applied after validation

*Discuss the basis for any modifications to the proposed test method protocol that were made based on results from validation studies.*

The highly detailed method protocol (Appendix A) also allows for omission of the centrifugation step of the blood/sample mixture. However, in order to reduce the variability of the assay to a minimum, the separation of blood and supernatant was obligatory for the final validation study (Appendix A; see also 2.1).

The test can easily be adjusted to a quantitative assay as described in the detailed method protocol. However, the assay has now been validated as a qualitative assay, by means of the PM.

## 2.7 Differences with similar test methods

*If applicable, discuss any differences between the protocol for the proposed test method and that for a comparable validated test method with established performance standards.*

Not applicable.

BRD: WB/IL-1

March, 2006

### 3 Substances Used for Validation

#### 3.1 Selection of substances used

*Describe the rationale for the chemicals or products selected for use in the validation process. Include information on the suitability of the substances selected for testing, indicating any chemicals that were found to be unsuitable.*

Selected test items were medicinal products available on the market. Released clinical batches were considered clean, i.e. containing no detectable pyrogens. To test the specificity, sensitivity and the reproducibility of the proposed test method, the products were spiked with pyrogen. For the present studies endotoxin (LPS) was selected as the model pyrogen, since it is well defined, standardized and readily available.

For the sensitivity and specificity the test items were assessed at their MVD. The MVD is the quotient of the ELC and the detection limit. The European Pharmacopoeia prescribes for various types of parenterals the amount of endotoxin that is maximally allowed in a medicinal product, i.e. the ELC, taking into consideration the dose, the route of administration and the dosing regimen of the product.

The aim of the study was to discriminate between negative and positive samples. Based on the selected pyrogen threshold value (see 4.1) and the PM applied, positive samples were defined as containing 0.5 EU/ml or more. Hence, to determine the MVD, the value of 0.5 EU/ml was defined as the detection limit.

Test items were assessed as such (negative product control), spiked with endotoxin at 0.5 IU/ml (positive product control) and after spiking with endotoxin at 5 levels (blinded samples). In addition a negative control (saline) and positive control (0.5 EU/ml in saline) were included to establish assay validity.

For reproducibility, the test items were tested, at a predefined dilution above the MVD, independently in 3 different laboratories, 3 times each. Based on the selected pyrogen threshold value (see 4.1) and the PM applied, positive samples were defined as containing 0.5 EU/ml or more. The test items were tested after spiking with endotoxin at four levels. For no other reasons but practical ones, i.e. availability of test materials, different test items were selected for this part of the validation study.

It was determined earlier whether candidate test items interfered with the outcome of the proposed test method. Interference was considered when the response of endotoxin in the diluted test item was below 50% or above 200% of the response of endotoxin in saline (spike-recovery). It was shown that none of the test items interfered with the assay at the selected dilutions (data not shown).

#### 3.2 Number of substances

*Discuss the rationale for the number of substances that were tested.*

A total of 13 test items were selected for the validation study (see 3.3): 10 test items for determining sensitivity and specificity (table 3.3.1), 3 different test items for determining reproducibility (table 3.3.2). Test items and their spikes were appropriately blinded by ECVAM before distribution to the participating testing facilities.

BRD: WB/IL-1

March, 2006

For sensitivity and specificity, each test item was tested after spiking at its individual MVD. Hence they each came with their own specific set of 5 endotoxin spike solutions: 0.0, 0.25, 0.5, 0.5 and 1.0 EU/ml. Simple logistics limited the amount of test items for this part of the validation study to 10. Since test items were assessed with 5 different endotoxin levels at 3 independent test facilities, this yielded a total of 150 data points, biometrically considered to be sufficient for further analysis.

For reproducibility each test item was spiked at 4 different levels (0.0, 0.0, 0.5 and 1.0 EU/ml) and tested at specified dilutions, 3 times at 3 laboratories.

### 3.3 Description of substances used

**Table 3.3.1:** Test items (parenteral drugs) used for determining sensitivity and specificity

Drug	code	Source	Agent	Indication	MVD (-fold)
<b>Glucose 5% (w/v)</b>	GL	Eifel	Glucose	nutrition	70
<b>Ethanol 13% (w/w)</b>	ET	B.Braun	Ethanol	diluent	35
<b>MCP®</b>	ME	Hexal	Metoclopramid	antiemetic	350
<b>Orasthin®</b>	OR	Aventis	Oxytocin	initiation of delivery	700
<b>Binotal®</b>	BI	Aventis	Ampicillin	antibiotic	140
<b>Fenistil®</b>	FE	Novartis	Dimetindenmaleat	antiallergic	175
<b>Sostril®</b>	SO	GlaxoSmithKline	Ranitidine	antiacidic	140
<b>Beloc®</b>	BE	Astra Zeneca	Metoprolol tartrate	heart dysfunction	140
<b>Drug A*</b>	LO	-	0.9% NaCl	-	35
<b>Drug B*</b>	MO	-	0.9% NaCl	-	70

\*Drugs A and B were included as saline controls using notional ELCs.

*Negative control:* 0.9% clinical stock saline solution.

*Positive control:* WHO-LPS 94/580 (*E. coli* 0113:H10:K-), 0.5 EU/ml in clinical stock saline.

**Table 3.3.2:** Test items (parenteral drugs) used for determining reproducibility.

Drug	Source	Agent	Indication
<b>Gelafundin®</b>	Braun melsungen	Gelatin	Transfusion
<b>Jonosteril®</b>	Fresenius	Electrolytes	Infusion
<b>Haemate®</b>	Aventis	Factor VIII	Hemophilia

*Negative control:* 0.9% clinical stock saline solution.

*Positive control:* WHO-LPS 94/580 (*E. coli* 0113:H10:K-), 0.5 EU/ml in clinical stock saline.



BRD: WB/IL-1

March, 2006

### 3.4 Sample coding procedure

*Describe the coding procedures used in the validation studies.*

All test items are registered medicinal products and were obtained from a pharmaceutical supplier. Test items and endotoxin spiking samples were prepared, blinded where appropriate and coded under GLP by personnel from ECVAM, Italy. These were then taken over by the Paul-Ehrlich Institute, Germany, for allocation and shipment to each of the appropriate test facilities participating in the study.

For the sensitivity and specificity part of this study, test items and their respective spikes (5 per test item) were all blinded. For reproducibility testing, only the spikes (4) were blinded, the test items were not.

### 3.5 Recommended reference chemicals

*For proposed test methods that are mechanistically and functionally similar to a validated test method with established performance standards, discuss the extent to which the recommended reference chemicals were tested in the proposed test method. In situations where a listed reference chemical was unavailable, the criteria used to select a replacement chemical should be described. To the extent possible, when compared to the original reference chemical, the replacement chemical should be from the same chemical/product class and produce similar effects in the in vivo reference test method. In addition, if applicable, the replacement chemical should have been tested in the mechanistically and functionally similar validated test method. If applicable, the rationale for adding additional chemicals and the adequacy of data from the in vivo reference test method or the species of interest should be provided.*

The reference pyrogen material used was the international endotoxin standard WHO-LPS 94/580 (*E. coli* 0113:H10:K-). Where appropriate, the material was diluted in clinical saline solution (0.9%(w/v) sodium chloride). The saline was also used as negative control (blank).

BRD: WB/IL-1

March, 2006

## 4 *In vivo* Reference Data on Accuracy

### 4.1 Test protocol *in vivo* reference test method.

*Provide a clear description of the protocol(s) used to generate data from the in vivo reference test method. If a specific guideline has been followed, it should be provided. Any deviations should be indicated, including the rationale for the deviation.*

For ethical reasons, no rabbit pyrogen tests were performed for this study. However, Dr. U. Lüderitz-Püchel, Paul-Ehrlich Institute, Germany, kindly provided historical data, accumulated over several years, from 171 rabbits (Chinchilla Bastards). The respective Pharmacopoeia's do not prescribe a rabbit strain for the *in vivo* pyrogen test, but Chinchilla rabbits are reported as a relatively sensitive strain for pyrogen testing.

The rabbits were injected with endotoxin and their rise in body temperature over the next 180 minutes was recorded (figure 4.1.1). From these data it was established that 50% of the rabbits got fever when treated with endotoxin at 5 EU/kg (Hoffmann et al, 2005a). Fever in rabbits is defined as a rise in body temperature over 0.55°C. On the basis of these historical animal data and corrected for the maximal volume allowed in rabbits, i.e. 10 ml per animal, a pyrogen threshold value of 0.5 EU/ml was defined for the PM in the proposed test method.


### 4.2 Accuracy

*Provide the in vivo reference test method data used to assess the accuracy of the proposed test method. Individual human and/or animal reference test data, if available, should be provided. Provide the source of the reference data, including the literature citation for published data, or the laboratory study director and year generated for unpublished data.*

As mentioned, no animal studies were done for ethical reasons. However, a theoretical assumption on specificity and sensitivity can be made (Hoffmann et al, 2005a). Taking the prevalence of the different final concentrations of LPS in the 5 spikes into account (1.0 EU/ml: 20%; 0.5 EU/ml: 40%; 0.25 EU/ml: 20% and 0.0 EU/ml: 20%) and calculating probabilities of misclassification using the chosen study design and defined threshold of pyrogenicity, i.e. 0.5 EU/ml, the theoretical sensitivity of the rabbit pyrogen test is 57.9% and the theoretical specificity of the rabbit pyrogen test is 88.3%.

BRD: WB/IL-1

March, 2006



**Figure 4.1.1** Dose-temperature of standard endotoxin applied to Chinchilla Bastards (n=171). Rabbits were treated with 1 ml saline containing 0, 5, 10, 15 and 20 EU of *E. coli* LPS (WHO-LPS 94/580 (*E. coli* O113:H10:K)) and their body temperature was measured over 180 min. Linear regression analysis was performed after logarithmic transformation of the data. Data are shown as dots to which a jitter-effect was applied in order to be able to distinguish congruent data. The full line depicts the linear regression whereas the dashed lines represent the 95%-confidence bounds. Furthermore, a horizontal line for a 0.55°C raise of temperature is added which is often defined as the rabbit threshold for fever. At the interception point of this line and the regression line 50% of the rabbits are to be expected to develop fever.

### 4.3 Original records

*If not included in the submission, indicate if original records are available for the in vivo reference test method data.*

The recognition of pyrogenic substances as bacterial by-products and the identification of a variety of pyrogenic agents enabled the development of a proper test to demonstrate non-pyrogenicity of the pharmaceutical product. As early as the 1920s, studies were done to select the most appropriate animal model. Results indicated that most mammals had a pyrogenic response, but only a few, including rabbits, dogs, cats, monkeys and horses showed a response similar to that in humans. For practical reasons, other species but rabbits and dogs were considered not practical. In 1942, Co Tui & Schrifft described that rabbits are less thermo-stable as compared to dogs. Hence, rabbits are more suited for the purpose of testing for the absence of pyrogens, since a negative result is more significant.

### 4.4 Quality of data

*Indicate the quality of the in vivo reference test method data, including the extent of GLP compliance and any use of coded chemicals.*

Documented procedures were employed that were GLP-concordant. These were quality assured by quality assurance officers from ECVAM.

BRD: WB/IL-1

March, 2006

#### 4.5 Toxicology

*Discuss the availability and use of relevant toxicity information from the species of interest (e.g., human studies and reported toxicity from accidental or occupational exposure for human health-related toxicity testing).*

Over time, a number of studies were done to correlate the rabbit test to pyrogenic reactions in humans. A conclusive study by Greisman and Hornick, published in 1969, who compared three purified endotoxin preparations (*Salmonella typhosa*, *E. Coli* and *Pseudomonas*) in New Zealand rabbits and in male volunteers, showed that the induction of a threshold pyrogenic response, on a weight basis, was similar to rabbit and man. At higher doses, rabbits respond less severe as compared to man.

#### 4.6 Background on assay performance

*Discuss what is known or not known about the accuracy and reliability of the in vivo reference test method.*

As mentioned, no animal studies were done for ethical reasons. However, a theoretical assumption on specificity and sensitivity can be made (Hoffman et al, 2005a) Taking the prevalence of the different final concentrations of LPS in the 5 spikes into account (1.0 EU/ml: 20%; 0.5 EU/ml: 40%; 0.25 EU/ml: 20% and 0.0 EU/ml: 20%) and calculating probabilities of misclassification using the chosen study design and defined threshold of pyrogenicity, i.e. 0.5 EU/ml, the theoretical sensitivity of the rabbit pyrogen test is 57.9% and the theoretical specificity of the rabbit pyrogen test is 88.3%.

BRD: WB/IL-1

March, 2006

## 5 Test Method Data and Results

### 5.1 Test method protocol

*Describe the proposed test method protocol used to generate each submitted set of data. Any differences from the proposed test method protocol should be described, and a rationale or explanation for the difference provided. Any protocol modifications made during the development process and their impact should be clearly stated for each data set.*

The detailed method protocol for the WB/IL-1 test is provided in the Appendix A of this BRD. It includes the precise step-by-step description of the test method, including the listing of all the necessary reagents and laboratory procedures for generating data. For two steps during validation a part of the protocol was adapted to contain a detailed description of the dilution of the samples and the spiking with WHO-LPS. The relevant part of the protocol is detailed in this section as well. Both protocols (see also 2.1) are attached in the Appendix A. The validity criteria and the detailed statistical analysis described in section 5.3 of this BRD were applied to analyse the data produced during validation.

To assess the reliability of the test method a series of experiments were conducted in the developing laboratory (DL). As a start, only blanks (saline, 0 EU/ml) and spikes of WHO-LPS in saline were tested. These experiments are summarised in table 5.1.1.

**Table 5.1.1** : summary of experiments with WHO-LPS in saline

Experiment	Spikes (EU/ml) in saline	n (per spike)	Repetitions of experiment	N
1A	0; 0.25; 0.5	20	1	60
1B	0; 0.063; 0.125; 0.25; 0.5	12	1	60
2A	0; 0.25; 0.5	20	3	180
2B	0; 0.25; 0.5	20	3	180

The collected data were used to answer questions regarding the nature of the distribution, the variance and its behaviour over the range of response in replicated measurements under identical conditions. In addition, intralaboratory reproducibility was assessed by the maintenance of minimum criteria, e.g. a detection limit below an a-priori chosen positive control or a dose-dependent standard curve (table 5.1.1, experiment 1b). With the data of this experiment an assessment of the limit of detection of the test can be done by calculating the smallest spike, which can be discriminated from the blank. Intralaboratory reproducibility was assessed by the maintenance of minimum criteria, e.g. a detection limit below an a-priori chosen positive control of a dose dependent standard curve.

The WB/IL-1 method was transferred from the DL to two other laboratories (denoted as naive laboratory 1 [NL1] and naive laboratory 2 [NL2]). A large-scale dose response experiment was performed by all three laboratories. For this study 6 or 7 concentrations were tested in a dose response curve (typically 0; 0.125; 0.25; 0.5; 1; 2; 4 EU/ml, at least 8 replicates) and all laboratories had to meet the validity criteria as laid down in the method protocol before the studies with medicinal substances were conducted.

BRD: WB/IL-1

March, 2006

The **(intra- and interlaboratory) reproducibility** was assessed by testing 3 different medicinal substances, Gelafundin, Jonosteril and Haemate (described in table 3.3.2, section 3.3.). Test items and their spikes were appropriately blinded. Test items were tested, at a predefined dilution above the MVD, independently in 3 laboratories, 3 times each. Test items were tested after spiking with WHO-LPS at four different levels, the spikes were blinded and coded by QA ECVAM. In addition a negative control (saline) and positive control (0.5 EU/ml) in saline were included to establish assay validity. Although this part of the study was designed for assessment of reproducibility, a preliminary estimate of the accuracy could be derived from the data. Applying the PM to the results and evaluating the concordance in a two-by-two contingency table assessed accuracy.

To assess **accuracy** of the proposed test method 10 substances (listed in table 3.3.1), were spiked with five different concentrations of the WHO-LPS (one of which is negative). To permit the application of the chosen PM, each drug was diluted to its individual MVD, which has been calculated using the ELCto that drug (listed in table 3.3.1.) Each substance had their own specific set of endotoxin spike solution, ensuring that after spiking the undiluted drug, it contained 0.0; 0.25; 0.5; 0.5 and 1.0 EU/ml respectively when tested at its MVD. A detailed description of the sample preparation was supplied to the three independent laboratories (shown in table 5.1.2). To put more weight to the result of this part of the validation, the spikes were blinded and coded by QA ECVAM. The raw data of the WB/IL-1 assay are shown in paragraph 5.2 Accuracy was assessed by applying the PM to the results and evaluating the concordance in a two by two table. As intralaboratory reproducibility was (successfully) shown in previous experiments, only interlaboratory reproducibility was assessed in this phase.

**Table 5.1.2:** Sample preparation for the testing of 10 substances spiked with 5 different concentrations of WHO-LPS.

<i>unblinded</i>			<i>blinded</i>				
dilution of drug up to MVD ↓			spiking of <b>undiluted</b> drug: 0.5 ml each				
diluted drug	NPC	PPC	+ 23.3 µl of Spike 1	+ 23.3 µl of Spike 2	+ 23.3 µl of Spike 3	+ 23.3 µl of Spike 4	+ 23.3 µl of Spike 5
0.5 ml	+ 25 µl saline	+ 25 µl PPC-LPS-spike *					
		(final conc. = 50 pg/ml)	<b>dilution to MVD</b> ↓				
	test	test	test	test	test	test	test

\* PPC-LPS-spike contains 1050 pg/ml = 21fold 50 pg/ml

**NPC** = Negative Product Control, **PPC** = Positive Product Control, **MVD** = Maximal Valid Dilution


BRD: WB/IL-1

March, 2006

**5.2 Accuracy and reliability**

*Provide all data obtained to evaluate the accuracy and reliability of the proposed test method. This should include copies of original data from individual animals and/or individual samples, as well as derived data. The laboratory’s summary judgment regarding the outcome of each test should be provided. The submission should include data (and explanations) from all studies, whether successful or not.*


See figures 5.2.1, 5.2.2, 5.2.3, 5.2.4, 5.2.5 (A, B and C), 5.2.6 and 5.2.7 (A and B).




**Figure. 5.2.1:** Coefficient of variation (CV) of WHO-LPS spikes (4 replicates) relative to the mean OD (readout of the IL-1 ELISA).

BRD: WB/IL-1

March, 2006



**Figure. 5.2.2:** Boxplots with OD values of 20- replicates (left) or 12 replicates (right) of WHO-LPS spikes in saline at various concentrations. (readout of the IL-1 ELISA).




**Figure. 5.2.3:** Boxplots OD values of the response of 3 different blood donations from one healthy volunteer on consecutive days with WHO-LPS (IU/ml) in saline at 0.0 IU/ml (Blank) or 0.5 IU/ml (Spike) (readout of the IL-1 ELISA).




BRD: WB/IL-1

March, 2006




**Figure 5.2.4:** Boxplots OD values of WHO-LPS (IU/ml) in saline at 0.0 (Blank) , 0.25 IU/ml (S0.25) or 0.5 IU/ml. (S0.5) with 3 different operators (readout of the IL-1 ELISA).



**Figure 5.2.5:** Boxplots OD values of the response of 8 individual donors to WHO-LPS (IU/ml) in saline at 0.0 IU/ml (bl.x) or 0.5 IU/ml. (S.x) (readout of the IL-1 ELISA).

BRD: WB/IL-1


March, 2006



**Figure 5.2.6 A:** Three different drugs were spiked (blinded) with WHO-LPS at 0.0, 0.0, 0.5 and 1.0 IU/ml, respectively. Experiment was run 3 time independently at three different laboratories. Here the results of the Konstanz laboratory (readout of the IL-1 ELISA). G = Gelafundin; J = Jonestrelil; H = Heamate. C- = negative control (saline); C+ = positive control (0.5 IU/ml in saline).

BRD: WB/IL-1


March, 2006



**Figure. 5.2.6 B:** Three different drugs were spiked (blinded) with WHO-LPS at 0.0, 0.0, 0.5 and 1.0 IU/ml, respectively. Experiment was run 3 time independently at three different laboratories. Here the results of the Bern laboratory (readout of the IL-1 ELISA). G = Gelafundin; J = Jonestrelil; H = Heamate. C- = negative control (saline); C+ = positive control (0.5 IU/ml in saline).

BRD: WB/IL-1


March, 2006



**Figure. 5.2.6 C:** Three different drugs were spiked (blinded) with WHO-LPS at 0.0, 0.0, 0.5 and 1.0 IU/ml, respectively. Experiment was run 3 time independently at three different laboratories. Here the results of the Oslo laboratory (readout of the IL-1 ELISA). G = Gelafundin; J = Jonestrelil; H = Heamate. C- = negative control (saline); C+ = positive control (0.5 IU/ml in saline).

BRD: WB/IL-1

March, 2006



**Figure. 5.2.7:** Coefficient of variation (CV) of different WHO-LPS spikes (0.0, 0.0, 0.5 and 1.0 IU/ml, respectively).from the experiments as shown in fig. 5.2.6 A-C.

G = Gelafundin; J = Jonestreril; H = Heamate.

NC = negative controle (saline); PC is positive conrole (0.5 IU/ml in saline).

### 5.3 Statistics

*Describe the statistical approach used to evaluate the data resulting from studies conducted with the proposed test method.*

A generally applicable analytical procedure was employed. This procedure includes a universal PM as well as quality criteria. First, a two-step procedure consisting of a variance-criterion and an outlier-test was performed. For this, the Dixon’s test (Barnett and Lewis, 1984), which is USP approved, was chosen with the significance level of  $\alpha=0.01$  and applied to identify and eliminate aberrant data.

Next, the negative and the respective positive control are compared to ensure a suitable limit of detection. For this, a one-sided t-test with a significance level of  $\alpha=0.01$  is applied to the ln-transformed data to ensure that the response to the positive control is significantly larger than that of the respective negative control.

Finally, the samples are classified as either negative or positive by the outcome of a one-sided version of the t-test, which is based on the assigned pyrogen threshold value. The final results will be given in 2 x 2 contingency tables (table 5.3.1). These tables allow for estimation of accuracy (sensitivity and specificity) and reproducibility of the proposed test method.

BRD: WB/IL-1

March, 2006

**Table 5.3.1:** 2x2 contingency table.

		<i>pre-defined class</i> <i>(“truth”)</i>		$\Sigma$
		<i>1</i>	<i>0</i>	
<i>Classification</i> <i>by test system</i> <i>and PM</i>	<i>1</i>	<i>a</i>	<i>b</i>	<i>a+b = n<sub>1</sub></i>
	<i>0</i>	<i>c</i>	<i>d</i>	<i>c+d = n<sub>0</sub></i>
$\Sigma$		<i>a+c = n<sub>1</sub></i>	<i>b+d = n<sub>0</sub></i>	<i>n</i>

Accuracy:

The most important statistical tool to determine accuracy (specificity and sensitivity) is the so-called PM (Hothorn, 1995). In general, it is a statistical model, which classifies a given drug by an objective diagnostic or deciding rule. The objective of a dichotomous result requires a clear cut PM, which assigns a drug in one of the two classes “pyrogenic for humans” and “non-pyrogenic for humans”. Since a threshold pyrogen value will be used, a one-sided test is appropriate for the task. Because the data are normalised by a ln-transformation, a t-test is chosen. Although the variances over the range of concentration converge by the transformation, the assumptions of equal variances do generally not hold true, because it depends on additional covariates. Therefore, the one sided Welch-t-test (Snedecor and Cochran, 1989) is applied. Due to the safety aspect of the basic problem, the hypotheses of the test are

$$H_0 : \mu_{S_{i,j}} > \mu_{S_+} \quad vs \quad H_1 : \mu_{S_{i,j}} < \mu_{S_+},$$

where  $\mu_{...}$  denotes the parameter of location of the respective ln-transformed distribution. This approach controls the probability of false positive outcomes directly by means of its significance level  $\alpha$ , which is chosen as 0.01, because it assumes hazard, respectively pyrogenicity, of the tested drug in  $H_0$ , and assures safety, i.e. non-pyrogenicity. The test statistic is

$$T_{S_{i,j}} = \frac{\bar{x}_{S_+} - \bar{x}_{S_{i,j}}}{\sqrt{\frac{s_{S_+}^2}{n_{S_+}} + \frac{s_{S_{i,j}}^2}{n_{S_{i,j}}}}}$$

BRD: WB/IL-1

March, 2006

The PM is built by means of the outcome of the test. Let 0 denote safety and 1 denote hazard. The classification of  $S_{i;j}$  is then determined by

$$S_{ij} = 0, \text{ if } T_{S_{ij}} > t_{0.99; n_{S+} + n_{S_{ij}} - 2},$$

$$S_{ij} = 1, \text{ else,}$$

where  $t_{0.99; n_{S+} + n_{S_{ij}} - 2}$  the 0.99-quantile of the t-distribution with  $n_{S+} + n_{S_{ij}} - 2$  degrees of freedom. The number of replicates for every control and sample, i.e.  $n_{...}$ , was harmonised to be four. Due to the possibility of removing one observation by the outlier test, the number of replicates could be reduced to three. The classification of a version of a drug is regarded as an independent decision. Therefore, the niveau  $\alpha$  is local.

Finally, the classifications of the drugs will be summarised in 2x2 contingency table (table 3). From these tables, estimates of the sensitivity ( $S_E$ ), i.e. the probability of correctly classified positive drugs and specificity ( $S_P$ ), i.e. the probability of correctly classified negative drugs, will be obtained by the respective proportions. Where

$$S_E = a / (a + c) * 100\%$$

and

$$S_P = d / (b + d) * 100\%.$$

Furthermore, these estimates will be accompanied by confidence intervals, which will be calculated by the Pearson-Clopper method (Clopper & Pearson, 1934). For example, let  $\hat{p}_{SE}$  denote the proportion, namely the sensitivity, under investigation. Then the confidence interval to a niveau  $\alpha$  is calculated as

$$\left[ P_{SE}^L = \frac{aF_{2a; 2(n_1 - a + 1); \frac{\alpha}{2}}}{n_1 - a + 1 + aF_{2a; 2(n_1 - a + 1); \frac{\alpha}{2}}}; P_{SE}^U = \frac{(a + 1)F_{2(a + 1); 2(n_1 - a); 1 - \frac{\alpha}{2}}}{n_1 - a + (a + 1)F_{2(a + 1); 2(n_1 - a); 1 - \frac{\alpha}{2}}} \right],$$

where  $F_{...}$  denotes the respective quantile of the F-distribution and  $n_1$  is the sample size of the positive drugs and  $a$  the number of correctly classified drugs.

By contaminating the drugs artificially and by defining a threshold value, which is assumed to be appropriate, the class of a drug is determined beforehand. The versions of drugs, which are effectively contaminated, but below the threshold dose, are considered to be negative, respectively safe, because their contamination is not crucial for humans in terms of ELC.

Reproducibility:

The analysis of the intra- and interlaboratory reproducibility was assessed from the three identical and independent runs conducted in each of 3 laboratories. The comparison of the three runs was carried out blindly such that the testing facility did not know the true classification of the sample, either pyrogenic or non-pyrogenic. By this procedure only

BRD: WB/IL-1

March, 2006

the randomness and reproducibility of the methods was assessed and not systematic errors, which may have arisen from other sources, e.g. logistics or preparation of the samples. This means that if a sample was (mis)classified in all three runs the result is reproducible regardless of the (mis)classification of the sample. Therefore, a measure of similarity, i.e. complete simple matching with equal weights, was preferred to the coefficient of correlation for 2x2 contingency tables.

The study was designed as follows: each laboratory had to conduct three independent runs with the same 12 samples (3 test items with 4 blinded spikes each) and two controls, i.e. saline as a negative control (C-) and a 0.5 EU/ml LPS-spike in saline as a positive controls (C+). The samples were derived from the three substances Gelafundine, Haemate and Jonosteril. Per run, each substance was blindly spiked twice with saline, once with 0.5 EU/ml LPS and once with 1 EU/ml LPS, which resulted in a balanced design with regard to positive and negative samples, i.e. samples expected to be pyrogenic and non-pyrogenic, respectively.

The three independent runs per testing facility provide the information on which the assessment of the intralaboratory reproducibility is based. The combined results of the three runs per testing facility were used to determine interlaboratory reproducibility. The correlation of the prediction (in terms of the Bravais-Pearson coefficient of correlation) between all runs is calculated, independent of whether that classification is true or false. A BP-correlation of 1 is calculated, if two runs gave exactly the same predictions for the twelve substances. If one run gives adverse classifications for all substances than the other, the correlation is -1. As these calculations do not need information of the true status of a sample, they were carried out blinded.

#### 5.4 Tabulated results

*Provide a summary, in graphic or tabular form, of the results.*

See tables 5.4.1 and 5.4.2.

**Table 5.4.1:** Results of testing 3 substances 3 times by 3 laboratories. Classifications after applying the prediction model (compare to fig. 5.2.5)

Sample	DL (Konstanz)			NL 1 (Bern)			NL 2 (Oslo)		
	Run 1	Run 2	Run 3	Run 1	Run 2	Run 3	Run 1	Run 2	Run 3
G-0 (1)	0	0	0	0	-	0	0	0	0
G-0 (2)	0	0	0	0	-	0	0	0	0
H-0 (1)	0	0	0	0	0	0	0	0	0
H-0 (2)	0	0	0	0	0	0	0	0	0
J-0 (1)	0	0	0	0	0	-	0	0	0
J-0 (2)	0	0	0	0	0	-	0	0	0
G - 0.5	1	1	0	0	-	1	1	1	0
H - 0.5	1	1	1	1	1	1	0	0	0
J - 0.5	1	0	0	1	1	-	0	0	0
G - 1	1	1	1	1	-	1	1	1	1
H - 1	1	1	1	1	1	1	0	0	0
J - 1	1	1	1	1	1	-	1	1	1

“0”denotes “non-pyrogenic”; “1” denotes “pyrogenic”; - denotes test invalid



BRD: WB/IL-1

March, 2006

**Table 5.4.2:** Results of the validation study of 10 drugs, spiked with WHO-LPS at 0.0, 0.25, 0.5, 0.5 and 1.0 IU/ml, respectively and tested in 3 different laboratories. Samples and spikes were blinded. Classifications after applying the prediction model (compare to fig. 5.2.7).

drug (code)	spike EU/ml	"truth"	results		
			Konstanz	PEI	Oslo
Beloc (BE)	0.00	0	0	0	0
	0.25	0	0	0	0
	0.50	1	0	1	0
	0.50	1	0	1	0
	1.00	1	0	1	1
Binotal (BI)	0.00	0	0	0	0
	0.25	0	0	0	0
	0.50	1	1	0	0
	0.50	1	1	1	0
	1.00	1	1	1	NA
Ethanol 13% (ET)	0.00	0	0	0	0
	0.25	0	0	0	0
	0.50	1	1	0	1
	0.50	1	1	0	1
	1.00	1	1	1	1
Fenistil (FE)	0.00	0	0	1	0
	0.25	0	0	1	0
	0.50	1	1	1	0
	0.50	1	1	1	1
	1.00	1	1	1	1
Glucose 5% (GL)	0.00	0	0	0	0
	0.25	0	0	0	0
	0.50	1	1	0	0
	0.50	1	1	0	1
	1.00	1	1	1	1
"Drug A" 0.9% NaCl (LO)	0.00	0	0	0	0
	0.25	0	0	0	0
	0.50	1	0	0	0
	0.50	1	0	NA	0
	1.00	1	1	1	1
MCP (ME)	0.00	0	0	0	0
	0.25	0	0	0	0
	0.50	1	1	1	0
	0.50	1	1	1	0
	1.00	1	1	1	1
"Drug B" 0.9% NaCl (MO)	0.00	0	0	0	0
	0.25	0	0	0	0
	0.50	1	1	1	0

BRD: WB/IL-1

March, 2006

drug (code)	spike EU/ml	“truth”	results		
			Konstanz	PEI	Oslo
	0.50	1	1	1	1
	1.00	1	1	1	1
Orasthin (OR)	0.00	0	0	0	0
	0.25	0	0	1	0
	0.50	1	1	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
Sostril (SO)	0.00	0	0	NA	0
	0.25	0	0	1	0
	0.50	1	0	1	1
	0.50	1	0	1	1
	1.00	1	1	1	1

“0”denotes “non-pyrogenic”; “1” denotes “pyrogenic”; NA is not assessed.

### 5.5 Coding of data

*For each set of data, indicate whether coded chemicals were tested, whether experiments were conducted without knowledge of the chemicals being tested, and the extent to which experiments followed GLP guidelines.*

Blinding of drugs and/or spikes is indicated with the data.

### 5.6 Circumstances

*Indicate the “lot-to-lot” consistency of the test substances, the time frame of the various studies, and the laboratory in which the study or studies were conducted. A coded designation for each laboratory is acceptable.*

In each part of the study, all samples are derived from one (clinical) lot.

### 5.7 Other data available

*Indicate the availability of any data not submitted for external audit, if requested.*

All relevant data were submitted with the present BRD.

BRD: WB/IL-1

March, 2006

## 6 Test Method Accuracy

### 6.1 Accuracy

*Describe the accuracy (e.g., concordance, sensitivity, specificity, positive and negative predictivity, false positive and negative rates) of the proposed test method compared with the reference test method. Explain how discordant results in the same or multiple laboratories from the proposed test were considered when calculating accuracy.*

Test method accuracy was assessed in two large scale experiments performed with the drugs outlined in table 3.3.1 and table 3.3.2 in section 3 respectively. As described before one experiment was performed in an early stage of the study with 3 different drugs, tested 3 times and the other final experiment all drugs were tested once in the three participating laboratories. From the first experiment a preliminary estimate of sensitivity and specificity can be figure out, whereas the second is regarded as the established accuracy for the WB/IL-1 assay.

**6.1.1 Preliminary estimate of the accuracy of the WB/IL-1 test.** In an early stage of the study a different concept for interference testing was used. The developing laboratories determined for each drug (outlined in table 3.3.2, section 3.3) the smallest dilution within the MVD that showed no interference or an acceptable degree of interference with the spike recovery. In general the lowest dilution of the sample allowing for a 50-200% spike recovery was chosen. In addition, the positive control (PC) set at 0.5 EU/ml saline was used as the classification threshold. The laboratory procedure as described in the method protocol was maintained throughout the study. Although it was realized there were some drawbacks to the concept for interference testing and applying the PC as a threshold, this small scale study allows for a preliminary estimate of the accuracy of the WB/IL-1 method.

It has to be noted that this part of the study was designed to provide an estimate of the intra- and inter laboratory reproducibility. Therefore it will also be discussed in detail in section 7 (Test Method Reliability).

According to the PM applied during an early phase of the study the outcome (positive/negative) is related to the positive control (PC=0.5 EU/ml). If absorbance of sample > absorbance of PC, then the sample is classified as positive. If absorbance of sample < PC, then the sample is classified as negative. While performing the experiments during this phase it was realized that there is a flaw between interference testing and the PM. After the interference testing, the lowest dilution of the sample allowing for a 50-200% spike recovery was chosen. It is obvious that even with a flawless repeatability of the assay; a spike recovery between 50%-100% would be classified as negative according to the preliminary PM. In addition, due to unforeseen problems with the preparations of the spike, the recovery of the spikes was far below 100%. (This is outside the scope of the study and will not be discussed). As a consequence of the employed preliminary setup of the study the sensitivity will be underestimated, and the specificity will be overestimated.

BRD: WB/IL-1

March, 2006

In short, three test substances were spiked with WHO-LPS at four levels (0, 0, 0.5 and 1.0 EU/ml respectively), which resulted in 12 samples with a balanced design with regard to positive and negative samples (i.e. samples expected to be pyrogenic and non-pyrogenic respectively). These 12 sample were three times tested in three laboratories. In total there were 108 classifications from 12 samples in 3 runs and in 3 laboratories (3x3x12=108). Results are described in detail in section 7. A 2x2 contingency table was constructed (table 6.1.1), from which the estimates of sensitivity and specificity can easily be derived.

**Table 6.1.1:** 2x2 contingency table. The prediction model applied to a preliminary study.

		True status of samples		Total
		+	-	
PM	+	36	0	36
	-	14	50	64
Total		50	50	100

The specifications of specificity and sensitivity described in section 5.3 were applied to these results and the specificity (Sp) of the WB/IL-1 assay is 100% ( $50/(50+0)*100\%$ ), 95% confidence interval [0.929;1]. The sensitivity (Se) equals 72% ( $36/(36+14)*100\%$ ), 95% confidence interval [0.575; 0.838]. As outlined previously the specificity is overestimated and the sensitivity is underestimated as a result of the design of this part of the study.

**6.1.2 Test method accuracy of the proposed WB/IL-1 method.** To assess accuracy of the proposed method, 10 substances (listed in table 3.1.1, section 3) were spiked with five different concentrations of the WHO-LPS (one of which is negative). Thus, in total, 50 samples have been tested in each laboratory.

To permit the application of the chosen PM, each drug was diluted to its individual MVD, which has been calculated using the ELC to that drug (listed in section 3). Lesser dilutions were tested by the DL, and showed no interference. Therefore interference was not expected at the individual MVD. Each substance had their own specific set of endotoxin spike solution, ensuring that after spiking the undiluted drug, it contained 0.0; 0.25; 0.5; 0.5 and 1.0 EU/ml respectively when tested at its MVD. A detailed description of the sample preparation was supplied to the three independent laboratories (shown in table 5.1.1 for convenience). To put more weight to the result of this part of the validation, the spikes were blinded and coded by QA ECVAM. The raw data and the graphical presentation of these raw data are shown in the section 5 (table 5.4.2).

Accuracy was assessed by applying the PM to the results (summarized in table 5.3.2) and evaluating the concordance in this section in a two by two contingency table (table 6.1.2). As described above 10 substances, spiked with 5 different WHO-LPS concentrations were tested in three laboratories and consequently a maximum of 150 data were available for analysis.

As intralaboratory reproducibility was successfully shown in previous experiments (analyzed in section 7), only one run performed in each laboratory was considered sufficient.

BRD: WB/IL-1

March, 2006

**Table 6.1.2:** 2x2 contingency table. Prediction model applied to the WB/IL-1 test result of 10 different substances assessed in three different laboratories.

		True status of samples		Total
		+	-	
PM	+	64	4	68
	-	24	55	79
Total		88	59	147

Of the 150 available data, only three sets of 4 replicates did not comply with the quality criteria as defined in the method protocol (CV <0.45) and were removed from the analysis. The specificity and sensitivity of the WB/IL-1 method could be estimated as described in section 5.3.

The specificity of the WB/IL-1 assay is 93.2% (55/(55+4)\*100%), 95% confidence interval [0.883;0.996]. The sensitivity equals 72.7% (64/(64+24) \*100%), 95% confidence interval [0.622;0.817]. (See table 6.1.3). The specificity varied from 78.9% up to 100% within the three laboratories, and the sensitivity varied from 62.1% up to 100%.

**Table 6.1.3:** Specificity and sensitivity of the WB/IL-1 assay

	N total	N correctly identified	proportion	95% CI lower limit	95% CI upper limit
Specificity (Sp)	59	55	93.2%	88.3%	99.6%
Sensitivity (Se)	88	64	72.7%	62.2%	81.7%

## 6.2 Concordancy to *in vivo* reference method

*Discuss results that are discordant with results from the in vivo reference method.*  
Not applicable.

## 6.3 Comparison with reference methods

*Discuss the accuracy of the proposed test method compared to data or recognized toxicity from the species of interest (e.g., humans for human health-related toxicity testing), where such data or toxicity classification are available. This is essential when the method is measuring or predicting an endpoint for which there is no preexisting method. In instances where the proposed test method was discordant from the in vivo reference test method, describe the frequency of correct predictions of each test method compared to recognized toxicity information from the species of interest.*  
Not applicable.

## 6.4 Strength and limitations

*State the strengths and limitations of the proposed test method, including those applicable to specific chemical classes or physical-chemical properties.*

It appears the proposed test is applicable to most classes of medicinal products, at least those that are non- or low-toxic to cells *in vitro*. In addition, the test may be employed to

BRD: WB/IL-1

March, 2006

assess pyrogenicity of various medical devices, such as (biological) bovine collagen bone implants.

### **6.5 Data interpretation**

*Describe the salient issues of data interpretation, including why specific parameters were selected for inclusion.*

No issues.

### **6.6 Comparison to other methods**

*In cases where the proposed test method is mechanistically and functionally similar to a validated test method with established performance standards, the results obtained with both test methods should be compared with each other and with the in vivo reference test method and/or toxicity information from the species of interest.*

Not applicable.

BRD: WB/IL-1

March, 2006

## 7 Test Method Reliability (Repeatability/Reproducibility)

### 7.1 Selection of substances

*Discuss the selection rationale for the substances used to evaluate the reliability (intralaboratory repeatability and intra- and interlaboratory reproducibility) of the proposed test method as well as the extent to which the chosen set of substances represents the range of possible test outcomes.*

The rationale for the selection of the substances is described in section 3.3. In short: for the present studies endotoxin (WHO-LPS) was selected as the model pyrogen, since it is well defined biological standard and readily available. Selected test substances were medicinal products available on the market. These batches are released by the manufacturers and comply with the Marketing Authorisation file and European Pharmacopoeia. Therefore these batches are considered to contain no detectable pyrogens. To test the method reliability the medical products were spiked with endotoxin.

### 7.2 Results

*Provide analyses and conclusions reached regarding the repeatability and reproducibility of the proposed test method. Acceptable methods of analyses might include those described in ASTM E691-92 (13) or by coefficient of variation analysis.*

In an early phase of the study, the intralaboratory repeatability and reproducibility of the test method was assessed in a series of experiments conducted in the DL. Series of blanks (saline, 0 EU/ml) and spikes of WHO-LPS in saline were tested. These experiments (1A, 1B, 2A, 2B and 2C) are summarized in table 7.2.1.

**Table 7.2.1:** Summary of experiments with WHO-LPS in saline.

Experiment	Spikes (EU/ml) in saline	n (per spike)	Repetitions of experiment	N
1A	0; 0.5	32	1	64
1B	0; 0.063; 0.125; 0.25; 0.5	12	1	60
2A	0; 0.5	12	3	72
2B	0; 0.25; 0.5	8	3	72
2C	0; 0.5	5	8	80

The data were used to answer questions regarding the nature of the distribution, the variance and its behavior over the range of response in replicated measurements under identical conditions. In addition reliability of the test method was assessed by the maintenance of minimum criteria, e.g. a detection limit below an a-priori chosen positive control or a dose-dependent standard curve (table 7.2.1, experiment 1B). With the data of this experiment an assessment of the limit of detection of the test can be done by calculating the smallest spike, which can be discriminated from the blank.

The second group of experiments was meant to analyze the variation in detail. For this purpose the major sources of variation were assessed separately, i.e. donor (experiment 2A) and operator (exp. 2B). A total of 348 data were collected and analyzed.

First the shape of the distribution at a spike was assessed (not shown). Most of the data showed normal-distribution.

Based on the experience that there is a monotone increasing relationship between the mean-responses and the variation (empirical variance or standard deviation), the analysis focuses on the coefficient of variation (CV). The CV should be distributed symmetric around a constant factor, if the mean-variance relationship is linear. A plot of all CVs against their corresponding means is shown in figure 5.2.1. From the figure it is clear that at this stage of the study, the CV for the blank is in six of 16 cases high. For the other spikes, first of all the 0.25 and the 0.5 EU/ml-spike, the variation for the sets of replicates is low. As only WHO-LPS was examined up to this point, it was envisaged that the CV would increase with other substances being tested. For CV criteria applied as a validity criteria of the WB/IL-1 assays was arbitrarily set at  $CV < 0.25$ .

The outliers were identified on the assumption of normally distributed data and this allows to apply a parametric test. At this point the Grubbs-test was chosen and the kind of outlier (lower or upper) and the significance level  $\alpha$  were recorded. Altogether there were 2 lower outliers and 10 upper outliers (equally divided between 5% and 1% significance level). Overall the amount of outliers is about 3%. The outliers were located all over the ELISA-plates and there was no obvious scheme. In addition, the raw data (plate-readouts) showed no obvious edge effects or trends.

The results of test 1A and 1B (figure 5.2.2) show that (after removal of outliers in the blank) the 0.25 EU/ml of spike can be discriminated statistically from the blank and the highest spike (0.5 EU/ml) can be detected easily.

Test 2A was designed to assess the behavior of a donor in time. The blood was taken on three successive days. Data are presented in figure 5.2.3. The donor showed in general the same behavior on the three days. The small deviations in the height of the response are negligible. Hence, the variation of a suitable donor is low and is considered to be no critical issue in the WB/IL-1 assay.

Three operators in parallel, using blood from the same donor conducted experiment 2B (figure 5.2.4). In general, the data are similar, but it is obvious that the sensitivity of the assay seems to depend on the operator. But still the data of the 0.25 EU/ml spikes can easily be discriminated from their corresponding blanks.

The final experiment was designed to show the robustness of the assay with respect to different donors. Therefore 8 donors were involved and for each donor five replicates of each of the spikes (0; 0.5EU/ml) were generated. Data are presented in figure 5.2.5. For donors 5-8 the variability within the blank-replicates were high. Some variation in sensitivity for LPS between the donors is obvious, especially donor 5 shows a lower response. But every donor reacts to the 0.5 EU/ml-spike. This experiment reveals that there is a certain effect of the covariate "donor" which is however not crucial to a qualitative PM.



BRD: WB/IL-1

March, 2006

**In conclusion:** The most critical issue identified is the variation within the sets of blanks, but this is probably caused by the handling of the assay. The WB/IL-1 assay is robust against all examined variables. Although the experiments revealed an effect for the covariates “blood donor”, “operator” and “day”, the sensitivity of the assay is at least 0.25 EU/ml for all experiments, thus 0.5 EU/ml is always detectable. Therefore the intralaboratory repeatability is considered satisfactory. The 3% percentage outliers, as determined by the Grubbs test is considered acceptable. The validity criteria of the WB/IL-1-assay as recorded in the method protocol, are based on these experiments, i.e.  $CV < 0.25$ , lower limit of detection 0.25 EU/ml.

#### **Intra- and inter laboratory reproducibility.**

After transfer of the WB/IL-1 assays to two other laboratories, a dose response experiments was performed by all three laboratories. For this study 6 or 7 concentrations were tested in a dose response curve (typically 0, 0.125, 0.25, 0.5, 1, 2, 4 EU/ml, at least 8 replicates). A participating laboratory qualified for taking part in next part of the study by producing a dose response curve, with a limit of detection of at least 0.25 EU/ml and a  $CV < 0.25$  (data not shown.).

The intra- and interlaboratory reproducibility was assessed by testing 3 different medicinal substances, Gelafundin, Jonosteril and Haemate (described in table 3.3.2, section 3.3.). Test substances and their spikes were appropriately blinded. Test substances were tested, at a predefined dilution above the MVD, independently in 3 different laboratories, 3 times each. The three test substances were spiked with WHO-LPS at four levels (0, 0.5, 1.0 and 2.0 EU/ml respectively), which resulted in 12 samples with a balanced design with regard to positive and negative samples (i.e. samples expected to be pyrogenic and non-pyrogenic respectively. In addition a negative control (saline) and positive control (0.5 EU/ml in saline) were included to establish assay validity. To avoid interference, the DL performed interference testing in terms of the BET, i.e. 50-200% spike recovery, and decided on the dilution of the test substances. Dilutions chosen for Gelafundine, Haemate, Jonosteril were 1:2, 1:20 and 1:2 respectively. The data derived by the RIVM are taken as an example of the three laboratories. The raw data and a graphical presentation of the absorbance values are shown in section 5 (raw data exp.5 and fig. 5.2.5).

From the experiment with LPS-WHO only it was concluded that  $CV$  for the WB/IL-1 assay is  $< 0.25$ , which is acceptable. It was envisaged that the  $CV$  was likely to be higher when testing different substances (different matrices) and was assessed for the current set of data. A plot of all  $CV$ s for all sets of 4 replicates of a drug with a spike is shown in figure 5.2.7. From the figure it is clear that the  $CV$  for a set of 4 replicates of one spike concentration is usually below 0.45, which is considered acceptable for a biological assay. Only one set of data showed an exceptional high ( $CV > 1.1$ ) which is probably due to a pipetting error. For the remainder of the studies the  $CV$  criteria applied as validity criteria of the WB/IL-1 assays was arbitrarily set at  $CV < 0.45$ .

The analysis of the intralaboratory reproducibility was assessed from the three identical and independent runs conducted in each laboratory. The comparison of the three runs was

BRD: WB/IL-1

March, 2006

carried out blindly such that the laboratory did not know the true classification of the sample (either pyrogenic or non-pyrogenic). By this procedure only the randomness and reproducibility of the methods was assessed and not systematic errors, which may have arisen from other sources, e.g. logistics or preparation of the samples. This means that if a sample was misclassified in all three runs the result is 100% intralab reproducible (regardless of the misclassification of the sample).

According to the preliminary PM applied during this phase of the study the outcome (positive/negative) was related to the positive control (PC=0.5 EU/ml). If absorbance of sample > absorbance of PC, then sample is classified as being positive. If absorbance of sample < PC, sample is classified as negative (positive/pyrogenic = 1, negative/non-pyrogenic = 0).

During this phase it was realized that there is a flaw between interference testing and the PM. After the interference testing, the lowest dilution of the sample allowing 50-200% spike recovery was chosen. It is obvious that even with a flawless repeatability of the assay, a spike recovery between 50%-100% would be classified as negative according to the preliminary PM.

From the three independent runs summarized in table 5.4.1, the intralaboratory reproducibility can be calculated for the separate laboratories (table 7.2.2). For these calculations there is no need for information of the true status of the sample. A minimum criterion for the establishment of an assay is that experiment carried out with the same samples should result in a high concordance of classifications.

For NL1 the calculations were limited, because the sensitivity criterion, i.e. a significant difference between C- and C+, was not fulfilled for Gelafundine in run 2 and Jonosteril in run 3. This results in only 28 samples for NL1 instead of 36.

From table 7.2.2 it can be read that the intralaboratory reproducibility is very good (89 – 94%) for all three participating laboratories.

**Table 7.2.2** : Intralaboratory reproducibility, assessed by correlation between different runs. Result of testing 3 substances 3 times by 3 laboratories.

	<b>DL (Konstanz)</b>	<b>NL1 (Berne)</b>	<b>NL2 (Oslo)</b>
Run 1 - Run 2	92% (11/12)	100% (8/8)	100% (12/12)
Run 1 - Run 3	83% (10/12)	88% (7/8)	92% (11/12)
Run 2 - Run 3	92% (11/12)	NA	92% (11/12)
Mean	89%	94%	94%
Proportion showing the same result in 3 runs	83%	NA	92%

NA = not assessed for lack of sufficient data

BRD: WB/IL-1

March, 2006

The interlaboratory reproducibility of the WB/IL-1 method was assessed in a similar manner to the intralaboratory reproducibility. A summarizing method to combine the three runs per laboratory is considered not appropriate, because it would mask misclassification. Therefore each run of one laboratory was compared with all runs of another laboratory. This results optimally in 108 comparisons between the data sets of two laboratories. The measure of similarity is then the proportion of equally classified samples. These proportions are summarized in table 7.2.3, show that there is a good interlaboratory reproducibility of at least 68%.

**Table 7.2.3:** Interlaboratory reproducibility. assessed by interlaboratory correlations. Result of testing 3 substances 3 times by 3 laboratories.

Laboratories	Interlaboratory reproducibility	Number of equal predictions
DL – NL1	92%	77 / 84
DL – NL2	77%	83 / 108
NL1 – NL 2	68%	57 / 84
Mean	79%	

DL = Konstanz; NL1 = Bern; NL2 = Oslo

Also from the result of the large scale study (testing 10 substances spiked with 5 separate spikes), the interlaboratory reproducibility can be estimated (table 7.2.4). All the samples were correctly identified by one of the laboratories (DL). The reproducibility varied from 70% to 82% between two laboratories. All three laboratories found the same result for 27 out of 47 samples (57%).

**Table 7.2.4:** Interlaboratory reproducibility: Assessed by testing of 10 substances, spiked 5 times. One run of 50 samples by three different laboratories.

Laboratories	Interlaboratory Reproducibility	Number of equal predictions
DL - NL1	73%	35 / 48
DL - NL2	82%	40 / 49
NL1 – NL2	70%	33 / 47
Mean	75%	
same result in all laboratories	57%	27 / 47

DL = Konstanz; NL1 = PEI, Germany; NL2 = Oslo

**Conclusion:** It is shown that the intralaboratory reproducibility, assessed by the proportion of equally classified samples between different runs varies from 89% to 94% between the three participating laboratories. The interlaboratory reproducibility between two laboratories varied from 68% to 92% in one large scale blinded experiment and from 70% to 82% in the other large scale blinded experiment. All three participating laboratories predicted the same in respectively 79% and 57% of the measurements. It has

BRD: WB/IL-1

March, 2006

to be noted that a substantial part of the samples was 0.5 EU/ml, at or close to the arbitrary demarcation point of the WB/IL-1 assay

### **7.3 Historical data**

*Summarize historical positive and negative control data, including number of experiments, measures of central tendency, and variability.*

Not applicable.

### **7.4 Comparison to other methods**

*In cases where the proposed test method is mechanistically and functionally similar to a validated test method with established performance standards, the reliability of the two test methods should be compared and any differences discussed.*

Not applicable.

BRD: WB/IL-1

March, 2006

## **8 Test Method Data Quality**

### **8.1 Conformity**

*State the extent of adherence to national and international GLP guidelines (7-12) for all submitted data, including that for the proposed test method, the in vivo reference test method, and if applicable, a comparable validated test method. Information regarding the use of coded chemicals and coded testing should be included.*

The studies were done in accordance to the guidelines for GLP. Written protocols and approved standard operating procedures were followed during the entire course of the study. Deviations were recorded and, where appropriate, approved in amendments. All data are stored and archived. As mentioned, samples were appropriately blinded.

### **8.2 Audits**

*Summarize the results of any data quality audits, if conducted.*

No audits were conducted.

### **8.3 Deviations**

*Discuss the impact of deviations from GLP guidelines or any noncompliance detected in the data quality audits.*

Not applicable.

### **8.4 Raw data**

*Address the availability of laboratory notebooks or other records for an independent audit. Unpublished data should be supported by laboratory notebooks.*

All records are stored and archived by the contributing laboratories and available for inspection.

BRD: WB/IL-1

March, 2006

## 9 Other Scientific Reports and Reviews

### 9.1 Summary

*Summarize all available and relevant data from other published or unpublished studies conducted using the proposed test method.*

Relevant data obtained with the proposed method are described in a number of published studies and reports. The most important ones for this BRD are included in the Appendix B as hardcopies and referenced in Section 12, whereas for others only the references are given in section 14. In most of the study reports the WB/IL-1 is named *in vitro* pyrogen test or IPT.

The establishment of the whole blood test as an alternative to the rabbit pyrogen test as well as the comparison to the BET is described below.

Further applications were developed by adaptation to the basic whole blood test e.g. to measuring pyrogenic contaminations of medical devices and measuring the air quality in the working place and references are included in Section 14 in part 2 and 3.

A total of 96 batches of parenteral pharmaceuticals from 21 indication groups were tested using the WB/IL-1 test and compared to data from the rabbit and BET, if available (Jahnke et al, 2000). For these batches of parenteral drugs it was shown that the result of the three methods correlated well. In one case (an amino acid-containing infusion solution) a pyrogen-containing batch was clearly detected by all three testing systems. The other parenteral pharmaceuticals remained negative in all assays. It is worth mentioning that all the products could be tested in the whole blood test, in some cases after interfering factors had been excluded. A few drugs (e.g. dopamine) were found to affect the sensitivity of the WB/IL-1 assay and hence caused interference, but this could be overcome by dilution of the drug.

In a preliminary study (Fennrich et al., 1999), the suitability of the test was tested by determining the LPS retrieval in spiked pharmaceutical samples at the border line concentrations given in the Ph. Eur. for endotoxins (ELC), which should be detectable also using the human WB/IL-1 test.

Human serum albumin belongs to those substances that still are tested in the rabbit pyrogen test. Spreitzer et al (2002) compared the sensitivity of the rabbit assay with the WB/IL-1 assay using 29 defined human albumin samples: plain, spiked with 5 EU/ml and 10 EU/ml respectively. The unspiked samples were negative in both assays. Both the borderline 5 EU/kg and the 10 EU/kg partially led to results of the rabbit test (conducted with 3 rabbits), which would cause further testing with additional animals. In contrast, the human whole blood assay resulted in a 100% detection for the 5 EU/ml and 10 EU/ml endotoxine spike. The human whole blood test resulted in at least the same level of security for the products as the rabbit pyrogen test did. After further dilution of the 29 spiked albumin samples to contain 0.5 EU/ml, 18 samples were still positive in the WB/IL-1 assay but there were 11 negative results too.

In a manuscript of Schindler et al. (2003) the reactivity of human and rabbit blood *in vitro* towards Gram negative and Gram-positive stimuli were compared directly using an

BRD: WB/IL-1

March, 2006

*in vitro* whole blood test (endpoint; IL-1) for both species. The reactivity of the two species towards LPS was found to be similar, whereas human blood was more sensitive for LTA (lipoteichoic acid) than rabbit blood. The results suggested that the test with human blood to detect contaminations in e.g. parenteral drugs, might predict the human reaction to real life contamination better than the rabbit pyrogen test.

A Gram-positive standard derived from *B. subtilis* has been developed by the same research group (Konstanz University) and was reviewed in numerous different articles. This lipoteichoic acid, is BET negative which however reacts positive in the WB/IL-1 assay. Identification, isolation and purification of other Gram-positive stimuli are subject of ongoing research.

It is stressed throughout these studies using whole blood that only healthy donors not taking any medication must be used for testing pharmaceuticals. Various drugs such as cortisone suppress interleukin release and would therefore exclude a blood donor from the experiment. An infection can stimulate release, as reflected in an increased baseline value or an abnormally high interleukin response. Therefore, the WB/IL-1 test may only be used if samples have first been shown not to cause interference. The blood group of the human donors does not influence the results of the assay.

## 9.2 Discussion

*Comment on and compare the conclusions published in independent peer-reviewed reports or other independent scientific reviews of the proposed test method. The conclusions of such scientific reports and reviews should be compared to the conclusions reached in this submission. Any ongoing evaluations of the proposed test method should be described.*

The validation study summarised in this BRD is the first, which extensively addresses specificity and accuracy using actual medicinal products spiked with endotoxin. Hence, there are no comparing reports in independent peer-reviewed journals available. However, the validation study confirms conclusions of scientific reports. E.g. several preliminary studies (e.g. Jahnke et al. 2000, Fennrich et al. 1999, Spreitzer et al 2002) showed that the WB/IL-1 assay is suitable to test different types of pharmaceuticals. This finding is confirmed by the current validation study, where 11 different pharmaceuticals were tested. In addition, both studies indicate that (pyrogen free) batches which passed the current batch release scheme and are available on the market, show rarely a false positive reactivity in the WB/IL-1 assay. Jahnke's study was conducted by an experienced laboratory, whereas relatively inexperienced laboratories were also involved in the validation study. This may account for the less than 100% specificity in the validation study.

Finally, Charles River Endosafe offers the whole blood test under the name IPT (*In vitro* Pyrogen Test) worldwide in a highly standardized kit-version. Frequent symposia and workshops with coworkers of Charles River together with the University of Konstanz take place in order to train interested parties and introduce the IPT to users. The introduction and optimization of cryopreserved human whole blood is expected to overcome all final obstacles to standardization.

BRD: WB/IL-1

March, 2006

### 9.3 Results of similar validated method

*In cases where the proposed test method is mechanistically and functionally similar to a validated test method with established performance standards, the results of studies conducted with the validated test method subsequent to the ICCVAM evaluation should be included and any impact on the reliability and accuracy of the proposed test method should be discussed.*

As mentioned, *in vitro* monocyte activation test methods for the detection of pyrogenic contaminants are being developed over the course of the past two decades. A number of variants have been described, although the underlying principle of each variant remains the same. The test preparation is cultured with monocytoic cells, either as peripheral blood mononuclear cells, PBMC, (diluted) whole blood or cells of a monocytoic cell line such as MM6. Accuracy and specificity of these test methods are comparable, but in general methods using whole blood, PBMC and the MM6 cell line appear to perform best (Hoffmann et al, 2005b; summarized in table 9.3.1).

Table 9.3.1 summarises the performance of *in vitro* methods presented in the five BRDs and Table 9.3.2 compares the *in vivo* and *in vitro* pyrogen tests regarding their strengths, weaknesses, costs, time, limitations.

However, most studies (as this one) are done with model pyrogens and as yet little experience is available in the field, e.g. as part of the final batch release test-package. Experience and thus confidence in these methods will grow once regulatory authorities approve these methods and more manufacturers start to employ them. Then, on a case by case situation, it should be determined which method is best suited for the actual situation and demonstrates to pick out the appropriate, i.e. pyrogenic batches of the medicinal product.



BRD: WB/IL-1

March, 2006

**Table 9.3.1:** Summary of the performance of in vitro pyrogen tests based on monocytoid cells (see Tables 7.2.2; 7.2.4; 6.1.3)

Test	System	Read-out	Intralaboratory reproducibility (%)	Interlaboratory reproducibility (%)	Sensitivity (%)	Specificity (%)
<b>WB/IL-6</b>	whole blood	IL-6	DL: 83.3 NL1: 94.4 NL2: 100	DL-NL1: 85.4 DL-NL2: 85.4 NL1-NL2: 92.0	88.9	96.6
<b>WB/IL-1</b>	whole blood	IL-1 $\beta$	DL: 88.9 NL1: 95.8 NL2: 94.4	DL-NL1: 72.9 DL-NL2: 81.6 NL1-NL2: 70.2	72.7	93.2
<b>96-wells WB/IL-1<sup>1</sup></b>	whole blood	IL-1 $\beta$	-	DL-NL1: 88.1 DL-NL2: 89.7 NL1-NL2: 91.5	98.8	83.6
<b>CRYO WB/IL-1</b>	cryo whole blood	IL-1 $\beta$	-	DL-NL1: 91.7 DL-NL2: 91.7 NL1-NL2: 91.7	97.4	81.4
<b>KN CRYO WB/IL-1<sup>2</sup></b>	cryo whole blood	IL-1 $\beta$	-	DL-NL1: 83.3 DL-NL2: 100 NL1-NL2: 83.3	88.9	94.4
<b>PBMC/IL6</b>	PBMC	IL-6	DL: 94.4 NL1: 100 NL2: 94.4	DL-NL1: 84.0 DL-NL2: 86.0 NL1-NL2: 90.0	92.2	95.0
<b>PBMC-CRYO/IL-6<sup>3</sup></b>	PBMC	IL-6	-	DL-NL1: 96 DL-NL2: 76 NL1-NL2: 80	93.3	76.7
<b>MM6/IL-6</b>	MM6	IL-6	DL: 100 NL1: 94.4 NL2: 94.4	DL-NL1: 90.0 DL-NL2: 89.6 NL1-NL2: 83.3	95.5	89.8

DL = developing laboratory; NL1, NL2 = naive laboratory 1 and 2

1 = data provided in Section 13 of WB/IL-1 BRD

2 = data provided in Section 13 of CRYO WB/IL-1 BRD

3 = data provided in Section 13 of PBMC/IL-6 BRD

Table amended from Hoffmann et al 2005b; results with THP cells not included

BRD: WB/IL-1

March, 2006

**Table 9.3.2:** Comparison of the in vivo and in vitro pyrogen tests regarding their strengths, weaknesses, costs, time, limitations

	<b>Rabbit pyrogen test</b>	<b>BET / LAL</b>	<b>In vitro pyrogen test</b>
<b>Test materials</b>	Liquids	Clear liquids	Liquids, potentially cell preparations, solid materials
<b>Pyrogens covered</b>	All (possible species differences to humans for non-endotoxin pyrogens)	Endotoxin from Gram-negative bacteria	(probably) all
<b>Limit of detection (LPS)</b>	0,5 EU	0,1 EU (some variants down to 0,01 EU)	0,5 EU (validated PM), some variants down to 0,001 EU
<b>Ethical concerns</b>	Animal experiment	About 10% lethality to bled horseshoe crabs	Some assays: blood donation
<b>Costs*</b>	High (200-600\$/sample)	Low (50-150\$/sample)	Medium (100-350\$/sample)
<b>Time required</b>	27 h	45 min	24-30h**
<b>Materials not testable</b>	Short-lived radiochemicals, anesthetics, sedatives, analgetics, chemotherapeutics, immunomodulators, cytokines, corticosteroids	Most biologicals, glucan-containing preparations (herbal medicinal products, cellulose-filtered products), lipids, microsomes, cellular therapeutics	Not known (some of the materials not testable in rabbits require adaptations)
<b>Others</b>	No positive or negative control included, strain differences, stress affects body temperature	Potency of LPS from different bacterial species in mammals not reflected, false-positive for glucans	Possible donor differences, need to exclude hepatitis/HIV and acute infections / allergies of donors, dedifferentiation of cell lines

\* = We consulted the laboratories participating in the validation study and a consultant regarding the costs of the tests. The figures we received vary significantly depending on the facility (e.g. industry, contract laboratory, control authority), frequency of testing, specific test requirements, country, etc.

\*\* = interference testing might increase duration by 24 hours

BRD: WB/IL-1

March, 2006

## **10 Animal Welfare Considerations (Refinement, Reduction, and Replacement)**

### **10.1 Diminish animal use**

*Describe how the proposed test method will refine (reduce or eliminate pain or distress), reduce, or replace animal use compared to the reference test method.*

Depending on the medicinal product, one of two animal-based pyrogen tests is currently prescribed by the respective Pharmacopoeias, i.e. the rabbit pyrogen test and the bacterial endotoxin test (BET). The rabbit pyrogen test detects various pyrogens but alone the fact that large numbers of animals are required to identify a few batches of pyrogen-containing samples argues against its use. In the past two decades, the declared intention to refine, reduce and replace animal testing, has lowered rabbit pyrogen testing by 80% by allowing to use the BET as an alternative pyrogen test for certain medicinal products. Bacterial endotoxin is the pyrogen of major concern to the pharmaceutical industry due to its ubiquitous sources, its stability and its high pyrogenicity. With the BET, endotoxin is detected by its capacity to coagulate the amoebocyte lysate from the haemolymph of the American horseshoe crab, *Limulus polyphemus*, a principle recognised some 40 years ago (Levin and Bang, 1964). In the US, *Limulus* crabs are generally released into nature after drawing about 20% of their blood and therefore most of these animals survive. However, the procedure still causes mortality of about 30,000 horseshoe crabs per year, which adds to more efficient threats of the horseshoe crab population like its use as bait for fisheries, habitat loss and pollution.

The proposed test method is an alternative for the rabbit test and the BET. By replacing the rabbit test or the BET, the lives of rabbits and horseshoe crabs are spared.

### **10.2 Continuation of animal use**

*If the proposed test method requires the use of animals, the following items should be addressed:*

*10.2.1 Describe the rationale for the need to use animals and describe why the information provided by the proposed test method requires the use of animals (i.e., cannot be obtained using non-animal methods).*

Not applicable.

*10.2.2 Include a description of the sources used to determine the availability of alternative test methods that might further refine, reduce, or replace animal use for this testing. This should, at a minimum, include the databases searched, the search strategy used, the search date(s), a discussion of the results of the search, and the rationale for not incorporating available alternative methods.*

Not applicable.

*10.2.3 Describe the basis for determining that the number of animals used is appropriate.*

Not applicable.

BRD: WB/IL-1

March, 2006

*10.2.4 If the proposed test method involves potential animal pain and distress, discuss the methods and approaches that have been incorporated to minimize and, whenever possible, eliminate the occurrence of such pain and distress.*

Not applicable.

BRD: WB/IL-1

March, 2006

## 11 Practical Considerations

### 11.1 Transferability

*Discuss the following aspects of proposed test method transferability. Include an explanation of how this compares to the transferability of the in vivo reference test method and, if applicable, to a comparable validated test method with established performance standards.*

In general, the proposed test method is not unlike other bioassays and immunoassays that are performed routinely in many laboratories.

*11.1.1 Discuss the facilities and major fixed equipment needed to conduct a study using the proposed test method.*

No extraordinary facilities are required. General laboratory equipment for aseptic operations and analytical instruments for performing immunoassays, e.g. microtiter plate reader and –washer, are sufficient to perform the proposed test method.

*11.1.2 Discuss the general availability of other necessary equipment and supplies.*

All supplies and reagents are readily available on the market. In contrast, availability of sufficient rabbits of adequate weight and in good health for the *in vivo* reference test is sometimes reported a limitation.

### 11.2 Training

*Discuss the following aspects of proposed test method training. Include an explanation of how this compares to the level of training required to conduct the in vivo reference test method and, if applicable, a comparable validated test method with established performance standards.*

*11.2.1 Discuss the required level of training and expertise needed for personnel to conduct the proposed test method.*

The proposed test method requires personnel trained for general laboratory activities in cell biology and immunochemistry or biochemistry. Techniques they should master are not unlike cell culture (aseptic operations) and immunological techniques (especially ELISA). Such expertise is available in most if not all QC-laboratories.

*11.2.2 Indicate any training requirements needed for personnel to demonstrate proficiency and describe any laboratory proficiency criteria that should be met.*

Personnel should demonstrate that they master the execution of the test. The candidate should demonstrate to meet all the appropriate assay acceptance criteria and yield accurate results (outcome) using selected test items.

BRD: WB/IL-1

March, 2006

### 11.3 Cost Considerations

*Discuss the cost involved in conducting a study with the proposed test method. Discuss how this compares to the cost of the in vivo reference test method and, if applicable, with that of a comparable validated test method with established performance standards.*

Three factors contribute to the cost of the proposed test method: availability of monocytoid cells, cost of the reagents for the immunoassay and, last but not least, personnel.

Since the proposed test method is relatively more labor-intensive, it is estimated that the cost of the proposed test method is more than the BET or the *in vivo* reference test using rabbits. Obviously, a higher throughput of tests (runs/year) such as in a QC-laboratory of a multi-product facility or in a Contract Research Organization will significantly reduce the costs per assay.

However, especially with pharmaceuticals of biological origin, the proposed test method may be cost-effective, since these products all too often are incompatible with the BET and by their nature preclude the reuse of the rabbits.

### 11.4 Time Considerations

*Indicate the amount of time needed to conduct a study using the proposed test method and discuss how this compares with the in vivo reference test method and, if applicable, with that of a comparable validated test method with established performance standards.*

Essentially the test stretches two working days. On day one the testing materials are prepared and incubated overnight with the monocytoid cells. On the second day the amount of excreted cytokines is determined by immunoassay. The total time from start to result is approximately 24 hours.

It is thus concluded that the proposed test method will take more time when compared to the alternative tests, either the rabbit test or the BET. It should be noted that rabbits are tested prior to their first use by a sham test.

BRD: WB/IL-1

March, 2006

## 12 References

List all publications referenced in the submission.

**References in bold are included as hardcopies in Appendix B**

- Barnett, V., Lewis, T. (1984). Outliers in statistical data. 2<sup>nd</sup> edition, Chichester, US: John Wiley & Sons, pp 171-172.
- Beutler B, Rietschel ET (2003). Innate immune sensing and its roots: the story of endotoxin. Nature Rev Immunol. 3: 169-176.**
- Bleeker, W.K., de Groot, E.M., den Boer, P.J. et al (1994). Measurement of interleukin-6 production by monocytes for in vitro safety testing of hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol 22: 835-840.**
- Clopper, C. J., Pearson, E. S. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial. *Biometrika* 26: 404-413
- Co Tui & Schrift, M.H. (1942). A tentative test for pyrogen in infusion fluids. *Proc. Soc. Exp. Biol. Med.* 49: 320-330.
- Cooper JF, Levin J, Wagner Jr. HN (1971). Quantitative comparison of *in vitro* and *in vivo* methods for the detection of endotoxin. *J Lab Clin Med* 78: 138-145.
- Dinarello CA, O'Connor JV, LoPreste G, Swift RL (1984). Human leukocyte pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli. J Clin Microbiol 20: 323-329.**
- Dinarello CA (1999). Cytokines as endogenous pyrogens. J Infect Dis 179 (Suppl 2): S294-304.**
- Duff GW, Atkins E (1982). The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with amebocyte lysate gelation. J Immunol Methods 52: 323-331.**
- Fennrich S, Fischer M, Hartung T, Lexa P, Montag-Lessing T, Sonntag H-G, Weigandt M und Wendel A. (1999). Detection of endotoxins and other pyrogens using human whole blood. Dev. Biol. Standards 101:131-139**
- Fennrich S, Wendel A and Hartung T. (1999). New applications of the human whole blood pyrogen assay (PyroCheck). ALTEX 16:146-149**
- Greisman SE, Hornick RB (1969). Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc Soc Exp Biol Med 131: 1154-1158.**
- Hansen, E.W. and Christensen, J.D. (1990) Comparison of cultured human mononuclear cells, Limulus amebocyte lysate and rabbits in the detection of pyrogens. J Clin Pharm Ther. 15: 425-433.**
- Hartung T, Wendel A (1996). Detection of pyrogens using human whole blood. In Vitro Toxicol 9: 353-359.**
- Hartung T, Aaberge I, Berthold S et al (2001). Novel pyrogen tests based on the human fever reaction. Altern Lab Anim 29: 99-123.**
- Hoffmann, S., Luederitz-Puechel, U., Montag-Lessing, T., Hartung, T. (2005a). Optimisation of pyrogen testing in parenterals according to different pharmacopoeias by probabilistic modeling. Journal of Endotoxin Research 11(1): 26-31**

BRD: WB/IL-1

March, 2006

- Hoffmann S, Pertbauer A, Schindler S, et al. (2005b) Validation of novel pyrogen tests based on human monocytoid cell lines. J Immunol Methods, 298(1-2):161-173.**
- Hothorn, L. A. (1995). Biostatistical analysis of the 'control vs. k treatments' design including a positive control group. In: Testing principles in clinical and preclinical trials, pp 19-26, Stuttgart, Germany: Gustav Fischer Verlag.
- Jahnke M, Weigand, Sonntag H-G. (2000). Comparative testing for pyrogens in parenteral drugs using the human whole blood pyrogen test, the rabbit in vivo pyrogen test and the LAL test. European Journal of Parenteral Science 5(2):39-44.**
- Levin J, Bang FB (1964). A description of cellular coagulation in the Limulus. Bull Johns Hopkins Hosp 155: 337-345.
- Poole S, Thorpe R, Meager A, Gearing AJ (1988). Assay of pyrogenic contamination in pharmaceuticals by cytokine release from monocytes. Dev Biol Stand 69: 121-123.**
- Poole S, Selkirk S, Rafferty B, Meager A, Thorpe R, Gearing A (1989). Assay of pyrogenic contamination in pharmaceuticals by cytokine release. Proceedings of the European Workshop on detection and quantification of pyrogen. Pharmeuropa special Vol 1, November 1989: 17-18.**
- Poole S, Mistry Y, Ball C et al (2003). A rapid 'one-plate' *in vitro* test for pyrogens. J Immunol Methods 274: 209-220.**
- Schindler S, Bristow A, Cartmell T, Hartung T and Fennrich S. (2003). Comparison of the reactivity of human and rabbit blood towards pyrogenic stimuli. ALTEX 20:59-63**
- Snedecor, G. W., Cochran, W. G. (1989). Statistical methods, 8<sup>th</sup> edition, Ames, US: The Iowa State University Press.
- Spreitzer I, Fischer M, Hartzsch K, Lüderitz-Püschel U and Montag T. (2000). Comparative Study of Rabbit Pyrogen Test and Human whole Blood Assay on Human Serum Albumin. ALTEX 19 (Suppl. 1):73-75.**
- Taktak YS, Selkirk S, Bristow AF et al (1991). Assay of pyrogens by interleukin-6 release from monocytic cell lines. J Pharm Pharmacol 43: 578-582.**
- Tsuchiya S, Yamabe M, Yamaguchi Y et al (1980). Establishment and characterisation of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26 : 171-176.**
- Ziegler-Heitbrock HWL, Thiel E, Futterer A et al (1988). Establishment of a human cell line (MONO MAC 6) with characteristics of mature monocytes. Int J Cancer 41: 456-461.**



BRD: WB/IL-1

March, 2006

## **13 CATCH-UP VALIDATION: Human WB/IL-1 in vitro Pyrogen Test using 96-wells plates.**

### **13.1 Rationale**

Throughout the study described in the previous part of this BRD, tubes are employed as a container during the incubation of the blood sample. However using 96 wells plates as a container is obviously more convenient. Although a significant impact on the accuracy of the WB/IL-1 assay is not expected, the influence of 96-wells plate was studied in an additional catch-up validation study (trail plan attached in Appendix A), while applying the same study plan as in the main part of this BRD. This variant is indicated as the 96-wells WB/IL-1 method in the remainder of this section.

### **13.2 Test Method Protocol Components**

The method follows the original standard protocol, with the obvious exemption of using 96-wells plates during incubation of the fresh blood (20 µl per well) with the samples of interest. Details of the test procedure are given under point 7: 7A - fresh blood using 96-well plates in test method protocol CRYO WB/IL-1: *Human Whole Blood Pyrogen Test in 96-well Plates Using Fresh or Cryopreserved Blood*( *electronic file name: SOP CRYO WB IL 1*) which was used during the catch-up validation (see Appendix A). The released IL-1 □ is assessed using the standard IL-1 □ ELISA.

### **13.3 Substances Used for Validation**

The same 10 parenteral drugs used to determine sensitivity and specificity (see table 3.3.1.) were used for the catch-up validation. Again, each test item was tested after spiking at its individual MVD, thus came with their own specific set of 5 endotoxin spike solutions: 0.0, 0.25, 0.5, 0.5 and 1.0 EU/ml. The test items were assessed with 5 different endotoxin levels at 3 independent test facilities, yielding a total of 150 data points, biometrically considered to be sufficient for further analysis.

The same three drugs (table 3.3.2) as used for the prevalidation of the CRYO WB/IL-1 method (see BRD CRYO WB/IL-1) were employed. Each drug was tested at an interference free dilution and spiked with 0.0, 0.0, 0.5 and 1.0 EU/ml. The samples were tested at each of the 3 laboratories. The results were used to provide a preliminary estimate of the interlaboratory reproducibility and accuracy.

### **13.4 Preliminary estimate of the Test Method Accuracy**

In short, three test substances were spiked with WHO-LPS at four levels (0, 0, 0.5 and 1.0 EU/ml respectively), which resulted in 12 samples with a balanced design with regard to positive and negative samples (i.e. samples expected to be pyrogenic and non-pyrogenic respectively. These 12 samples were tested in three laboratories (See figure 13.4.1)

BRD: WB/IL-1

March, 2006




Figure 13.4.1: Prevalidation data for 96-wells WB/IL-1 of the three involved laboratories. The treatments and controls are abbreviated (indicating the endotoxin contamination in EU. (J = Jonosteril; G = Gelafundin; H = Haemate; C- = saline with 0 EU; C+ = positive control)

BRD: WB/IL-1

March, 2006

As Figure 13.4.1 only gives an indication about variability of replicates, the CVs were calculated for each treatment or control for all laboratories (Figure 13.4.2). In general the CVs were smaller than 30% and only two treatments produced a CV larger than 45%. Furthermore a tendency for larger CV of endotoxin-free samples/treatments was observed, as the background OD-level was lower compared to the equivalent assays, described in the main part of the BRD.




Figure 13.4.2: Coefficients of variation of the prevalidation data from 96-wells WB/IL-1 for the three involved laboratories. The treatments and controls are abbreviated indicating the endotoxin contamination in EU. (J = Jonosteril; G = Gelafundin; H = Haemate; C- = saline with 0 EU; C+ = positive control)

Application of the PM to these data resulted in the classifications summarized in Table 13.4.1. Ten out of the twelve spikes were classified in the same way in all laboratories. Comparing the laboratories pair wise, showed that 32 of the total of 36 single comparison, i.e. 88.9%, resulted in the same classification.

Assessing in the final step preliminarily the predictive capacity, revealed that all negative samples were classified correctly and that two 0.5-EU spikes (Konstanz: J-0.5; PEI: H-0.5), which are at the rabbit classification threshold, were classified false negative.

BRD: WB/IL-1

March, 2006

**Table 13.4.1:** Classification by the 96-wells WB/IL-1 of the spikes in the prevalidation in the three involved laboratories.

<b>drug</b>	<b>spike in EU</b>	<b>laboratory Konstanz</b>	<b>Qualis</b>	<b>PEI</b>
Jonosteril	0	0	0	0
	0	0	0	0
	0.5	0	1	1
	1	1	1	1
Gelafundin	0	0	0	0
	0	0	0	0
	0.5	1	1	1
	1	1	1	1
Haemate	0	0	0	0
	0	0	0	0
	0.5	1	1	0
	1	1	1	1

**Table 13.4.2:** Preliminary estimate of interlaboratory reproducibility: Assessed by testing of 3 substances, spiked 4 times. One run of 12 samples by three different laboratories.

<b>Laboratories</b>	<b>Interlaboratory Reproducibility</b>	<b>Number of equal predictions</b>
DL - NL1	91.7%	11 / 12
DL - NL2	83.3%	10 / 12
NL1 – NL2	91.7%	11 / 12
Mean	88.9%	
same result in all laboratories	83.3%	10 / 12

DL =Konstanz; NL1 = Qualis; NL2 = PEI

BRD: WB/IL-1

March, 2006

A 2x2 contingency table was constructed (table 13.4.3), from which a preliminary estimates of sensitivity and specificity can easily be derived.

**Table 13.4.3:** 2x2 contingency table. The prediction model applied to a preliminary validation study with 96-wells WB/IL-1. Three different substances were assessed in three different laboratories (derived from table 13.4.1)

		True status of samples		Total
		+	-	
PM	+	16	0	16
	-	2	18	20
Total		18	18	36

The specifications of specificity and sensitivity described in section 5.3 were applied to these results. The specificity (Sp) of the 96-wells WB/IL-1 assay is 100% and the sensitivity (Se) calculated for this data set is 88.9%. As outlined previously the specificity is overestimated and the sensitivity is underestimated as a result of the design of this part of the study.

**Conclusion:** Regarding the inherent variability of the assay method, the 96-wells WB/IL-1 showed good results. The result of the prevalidation show that the interlaboratory reproducibility and the predictive capacity in terms of specificity and sensitivity of the 96-wells WB/IL-1 are comparable with the WB/IL-1 using tubes.

**13.5 Test Method Accuracy**

To assess **accuracy** of the proposed test method 10 substances (listed in table 3.3.1), were spiked with five different concentrations of the WHO-LPS (one of which is negative). To permit the application of the chosen prediction model, each drug was diluted to its individual MVD, which has been calculated using the ELC to that drug (listed in table 3.3.1.) Each substance had their own specific set of endotoxin spike solution, ensuring that after spiking the undiluted drug, it contained 0.0; 0.25; 0.5; 0.5 and 1.0 EU/ml respectively when tested at its MVD. A detailed description of the sample preparation was supplied to the three independent laboratories (as shown in table 5.1.2). To put more weight to the result of this part of the validation, the spikes were blinded and coded by QA ECVAM. Accuracy was assessed by applying the PMI to the results and evaluating the concordance in a two by two table.

BRD: WB/IL-1

March, 2006

**Table 13.5.1:** Results of the validation study of 10 drugs, spiked with WHO-LPS at 0.0, 0.25, 0.5, 0.5 and 1.0 IU/ml, respectively and tested in 3 different laboratories. Samples and spikes were blinded. Classifications after applying the prediction model.

drug (code)	spike EU/ml	“truth”	results		
			PEI	Qualis	Novartis
<b>Beloc (BE)</b>	0.00	0	0	0	0
	0.25	0	1	0	0
	0.50	1	1	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
<b>Binotal (BI)</b>	0.00	0	0	0	0
	0.25	0	0	1	0
	0.50	1	1	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
<b>Ethanol 13% (ET)</b>	0.00	0	0	0	CV
	0.25	0	0	1	0
	0.50	1	1	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
<b>Fenistil (FE)</b>	0.00	0	0	0	0
	0.25	0	CV	1	1
	0.50	1	CV	1	1
	0.50	1	CV	1	1
	1.00	1	1	1	1
<b>Glucose 5% (GL)</b>	0.00	0	0	0	0
	0.25	0	0	1	1
	0.50	1	1	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
<b>"Drug A" 0.9% NaCl (LO)</b>	0.00	0	CV	0	0
	0.25	0	0	0	0
	0.50	1	CV	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
<b>MCP (ME)</b>	0.00	0	0	0	0
	0.25	0	0	0	1
	0.50	1	0	1	1
	0.50	1	1	1	1
	1.00	1	CV	1	1

BRD: WB/IL-1

March, 2006

drug (code)	spike EU/ml	"truth"	results		
			PEI	Qualis	Novartis
<b>"Drug B"</b>	0.00	0	0	0	0
<b>0.9% NaCl (MO)</b>	0.25	0	0	0	CV
	0.50	1	CV	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
<b>Orasthin (OR)</b>	0.00	0	0	0	0
<b>Syntocinon</b>	0.25	0	0	0	0
	0.50	1	1	1	1
	0.50	1	1	1	1
	1.00	1	1	1	1
<b>Sostril (SO)</b>	0.00	0	0	0	0
	0.25	0	CV	0	1
	0.50	1	1	1	CV
	0.50	1	1	1	1
	1.00	1	1	1	1

"0"denotes "non-pyrogenic"; "1" denotes "pyrogenic".

CV = sample showed a variability resulting in exclusion, i.e. CV > 45% and no significant outlier present. nq = not qualified according to quality criteria, i.e. failure of PPCs and PCs  
False classifications are in bold/colour type.

Of the 150 available data for the 96-wells WB/IL-1 method, eleven sets of 4 replicates showed a high variability resulting in exclusion, i.e. CV > 45% and no significant outliers present. Therefore 139 data in total could be used to estimate the specificity and sensitivity of the 96-wells WB/IL-1 method. The results are shown separately for each participating laboratory (table 13.5.2) as well as combined for all these laboratories (table 13.5.3).

The specificity that can be estimated from the available results for DL, NL1 and NL2 is 94.1%, 80% and 77.8% respectively. The estimated sensitivity of the 96-wells WB/IL-1 assay was excellent of all three participating laboratories: 96%, 100% en 100% respectively (calculated from results in table 13.1.2).

**Table 13.5.2:** 2x2 contingency table. Prediction model applied to the 96-wells WB/IL-1 test result of 10 different substances assessed in three different laboratories. Results of each laboratory separately (DL, NL1 and NL2= PEI, Qualis and Novartis respectively).

Results DL	True status of samples		Total
	+	-	
PM +	24	1	25
PM -	1	16	17
Total	25	17	42

BRD: WB/IL-1

March, 2006

Results NL1		True status of samples		Total
		+	-	
PM	+	30	4	34
	-	0	16	16
Total		30	20	50

Results NL2		True status of samples		Total
		+	-	
PM	+	29	4	33
	-	0	14	14
Total		29	18	47

The specificity of the combined results of the three laboratories of the 96-wells WB/IL-1 assay is 83.6% ( $46/(46+9) \times 100\%$ ), 95% confidence interval [0.712-0.922]. The sensitivity equals 98.8% ( $83/(83+1) \times 100\%$ ), 95% confidence interval [0.935-0.999]. (Summarized in table 13.5.3 and 13.5.4).

**Table 13.5.3** 2x2 contingency table. Prediction model applied to the 96-wells WB/IL-1 test result of 10 different substances assessed in three different laboratories. Combined results.

		True status of samples		Total
		+	-	
PM	+	83	9	92
	-	1	46	47
Total		84	55	139

**Table 13.5.4** Specificity and sensitivity of the 96-wells WB/IL-1 assay

	N total	N correctly identified	proportion	95% CI lower limit	95% CI upper limit
Specificity (Sp)	55	46	83.6%	0.712	0.922
Sensitivity (Se)	84	83	98.8%	0.935	0.999



BRD: WB/IL-1

March, 2006

### 13.6 Test Method Reliability (Reproducibility)

The interlaboratory reproducibility of the 96-wells WB/IL-1 method was assessed from the results of the validation test with 10 substances spiked with 5 separate spikes. The reproducibility varied from 88.1% to 91.5% between two laboratories. Also the estimated reproducibility between the three participating laboratories was very satisfactory (84.6%)

**Table 13.6.1.:** Interlaboratory reproducibility, 96-wells WB/IL-1: Assessed by testing of 10 substances, spiked 5 times. One run of 50 samples by three different laboratories.

Laboratories	Interlaboratory Reproducibility	Number of equal predictions
DL - NL1	88.1%	37 / 42
DL - NL2	89.7%	35 / 39
NL1 – NL2	91.5%	43 / 47
Mean	89.8%	
same result in all laboratories	84.6%	33 / 39

### 13.7 Conclusion

In this catch-up validation study it is shown that the interlaboratory reproducibility of the WB/IL-1 assay could be improved with the 96-wells approach. All three laboratories found the same in 84.6% of the result, whereas only 57% was predicted the same with the original WB/IL-1. Also the predictive capacity of the 96 wells test in terms of specificity and sensitivity was very promising. In this catch-up validation study the specificity of the 96-wells was lower than for the tubes (83.6% versus 93.2%), but still very satisfactory. However, the sensitivity was considerably improved (98.8% versus 72.7%). It appears that implementation of the 96-wells plates is a remarkable improvement of the well established WB/IL-1 test.

BRD: WB/IL-1

March, 2006

## 14 Supporting Materials (Appendices)

### 14.1 Standard operating procedure (SOP) of the proposed method

*Provide the complete, detailed protocol for the proposed test method.*

Appendix A includes the test method protocol *WB/IL-1: Human Whole Blood Pyrogen (electronic file name: SOP-WB IL 1)* and the protocol used for the validation study ("*Human Whole Blood Pyrogen Test - Standard Operating Procedure for the Validation Phase*" marked with internal identifier *Sop-WBT-KNv02*; electronic file name: *SOP WB-IL-1 validation*).

Regarding the WB/IL-1 using fresh blood and 96 well plates (Section 13 of this BRD), the method is described under point 7: 7A - fresh blood using 96-well plates in test method protocol *CRYO WB/IL-1: Human Whole Blood Pyrogen Test in 96-well Plates Using Fresh or Cryopreserved Blood (electronic file name: SOP CRYO WB IL 1)*.

The trial plan of the validation and catch-up validation study are also included in Appendix A.

### 14.2 Standard operating Procedure (SOP) of the reference method

*Provide the detailed protocol(s) used to generate reference data for this submission and any protocols used to generate validation data that differ from the proposed protocol.*

### 14.3 Publications

*Provide copies of all relevant publications, including those containing data from the proposed test method, the in vivo reference test method, and if applicable, a comparable validated test method with established performance standards.*

Not all of the publications cited in the BRD (see section 12) are included as hardcopies in Appendix B, e.g. publications on statistical methods are not given.

Remark: The same set of hardcopies was included into Appendix B of all of the 5 submitted BRDs. Therefore some of the publications in Appendix B might not be referenced in the current BRD nor included in the list of the publications in section 12. Three general publications were added, which are not cited in any BRD but might be useful as background information to the validation study: the ECVAM publications on validation (Balls et al, 1995; Curren et al, 1995; Hartung et al, 2004). Several publications were included, which either give more background information on the human fever reaction or report on specific studies using *in vitro* pyrogen tests.

#### Part 1:

##### *List of hard copies*

Andrade SS, Silveira RL, Schmidt CA, Junior LB, Dalmora SL. (2003) Comparative evaluation of the human whole blood and human peripheral blood monocyte tests for pyrogens. *Int J Pharm.* Oct 20;265(1-2):115-24.

BRD: WB/IL-1

March, 2006

- Balls et al. (1995) Practical aspects of the validation of toxicity test procedures. ECVAM Workshop Report 5. ATLA 23, 129-147.
- Beutler B, Rietschel ET (2003). Innate immune sensing and its roots: the story of endotoxin. *Nature Rev Immunol*. 3: 169-176.
- Bleeker, W.K., de Groot, E.M., den Boer, P.J. et al (1994). Measurement of interleukin-6 production by monocytes for in vitro safety testing of hemoglobin solutions. *Artif Cells Blood Substit Immobil Biotechnol* 22: 835-840.
- Carlin G, Viitanen E. (2003) In vitro pyrogenicity of a multivalent vaccine: Infanrix. *PHARMEUROPA*, 15(3), 418-423.
- Curren et al (1995) The Role of prevalidation in the development, validation and acceptance of Alternative Methods. ECVAM Prevalidation Task Force Report 1. ATLA 23, 211-217.
- De Groote, D., Zangerle, P.F., Gevaert, Y., Fassotte, M.F., Beguin, Y., Noizat-Pirenne, F., Pirenne, J., Gathy, R., Lopez, M., Dehart I., (1992). Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. *Cytokine* 4, 239.
- Dinarelli CA, O'Connor JV, LoPreste G, Swift RL (1984). Human leukocyte pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant *Escherichia coli*. *J Clin Microbiol* 20: 323-329.
- Dinarelli CA (1999). Cytokines as endogenous pyrogens. *J Infect Dis* 179 (Suppl 2): S294-304.
- Duff GW, Atkins E (1982). The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with amebocyte lysate gelation. *J Immunol Methods* 52: 323-331.
- Fennrich S, Wendel A and Hartung T. (1999). New applications of the human whole blood pyrogen assay (PyroCheck). *ALTEX* 16:146-149
- Fennrich S, Fischer M, Hartung T, Lexa P, Montag-Lessing T, Sonntag H-G, Weigandt M und Wendel A. (1999). Detection of endotoxins and other pyrogens using human whole blood. *Dev. Biol. Standards* 101:131-139
- Gaines Das et al (2004). Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis. *J. of Immunological Methods* 288, 165-177.
- Greisman SE, Hornick RB (1969). Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. *Proc Soc Exp Biol Med* 131: 1154-1158.
- Hansen, E.W. and Christensen, J.D. (1990) Comparison of cultured human mononuclear cells, *Limulus* amebocyte lysate and rabbits in the detection of pyrogens. *J Clin Pharm Ther.* 15: 425-433.
- Hartung T, Wendel A (1996). Detection of pyrogens using human whole blood. *In Vitro Toxicol* 9: 353-359.
- Hartung T, Aaberge I, Berthold S et al (2001). Novel pyrogen tests based on the human fever reaction. *Altern Lab Anim* 29: 99-123.
- Hartung et al (2004) A modular approach to the ECVAM principles on test validity. *ATLA* 32, 467-472.
- Hoffmann, S., Luederitz-Puechel, U., Montag-Lessing, T., Hartung, T. (2005). Optimisation of pyrogen testing in parenterals according to different

BRD: WB/IL-1

March, 2006

- pharmacopoeias by probabilistic modeling. *Journal of Endotoxin Research* 11(1): 26-31
- Hoffmann S, Peterbauer A, Schindler S, et al (2005). International validation of novel pyrogen tests based on human monocytoïd cells. *J Immunol Methods* 298: 161-173.
- Jahnke M, Weigand, Sonntag H-G. (2000). Comparative testing for pyrogens in parenteral drugs using the human whole blood pyrogen test, the rabbit in vivo pyrogen test and the LAL test. *European Journal of Parenteral Science* 5(2):39-44
- Nakagawa Y, Maeda H, Murai T. (2002) Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: comparison with a human whole blood culture test system and with the rabbit pyrogen test. *Clin Diagn Lab Immunol.* May;9(3):588-97.
- Pasare, C. and Medzhitov, R. (2003). Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. *Science* 299: 1033-1036.
- Pool EJ, Johaar G, James S, Petersen I, Bouic P. (1998) The detection of pyrogens in blood products using an ex vivo whole blood culture assay. *J Immunoassay.* May-Aug;19(2-3):95-111.
- Pool EJ, Johaar G, James S, Petersen I, Bouic P. (1999) Differentiation between endotoxin and non-endotoxin pyrogens in human albumin solutions using an ex vivo whole blood culture assay. *J Immunoassay.* Feb-May; 20(1-2):79-89.
- Poole S, Thorpe R, Meager A, Hubbard AJ, Gearing AJ (1988). Detection of pyrogen by cytokine release. *Lancet* 8577, 130.
- Poole S, Thorpe R, Meager A, Gearing AJ (1988). Assay of pyrogenic contamination in pharmaceuticals by cytokine release from monocytes. *Dev Biol Stand* 69: 121-123.
- Poole S, Selkirk S, Rafferty B, Meager A, Thorpe R, Gearing A (1989). Assay of pyrogenic contamination in pharmaceuticals by cytokine release. *Proceedings of the European Workshop on detection and quantification of pyrogen.* *Pharmeuropa special Vol 1*, November 1989: 17-18.
- Poole S, Musset MV (1989). The International Standard for Endotoxin: evaluation in an international collaborative study. *J Biol Stand* 17: 161-171.
- Poole S, Mistry Y, Ball C et al (2003). A rapid 'one-plate' in vitro test for pyrogens. *J Immunol Methods* 274: 209-220.
- Ray A, Redhead K, Selkirk S, Polle S (1991) Variability in LPS composition, antigenicity and reactivity of phase variants of *Bordetella pertussis*. *FEMS Microbiology Letters* 79, 211-218.
- Reddi, K., Nair, S.P. et al (1996). Surface-associated material from the bacterium *Actinobacillus actinomycetemcomitans* contains a peptide which, in contrast to lipopolysaccharide, directly stimulates fibroblast interleukin-6 gene transcription. *Eur. J. Biochem.* 236: 871-876.
- Schindler S, Bristow A, Cartmell T, Hartung T and Fennrich S. (2003). Comparison of the reactivity of human and rabbit blood towards pyrogenic stimuli. *ALTEX* 20:59-63.
- Schindler et al (2004) Cryopreservation of human whole blood for pyrogenicity testing. *Journal of Immunological Methods* 294, 89–100

BRD: WB/IL-1

March, 2006

- Schins RP, van Hartingsveldt B, Borm PJ. Ex vivo cytokine release from whole blood. A routine method for health effect screening. *Exp Toxicol Pathol.* 1996 Nov; 48(6):494-6.
- Spreitzer I, Fischer M, hartzsch K, Lüderitz-Püschel U and Montag T. (2000). Comparative Study of Rabbit Pyrogen Test and Human whole Blood Assay on Human Serum Albumin. *ALTEX* 19 (Suppl. 1):73-75
- Taktak YS, Selkirk S, Bristow AF et al (1991). Assay of pyrogens by interleukin-6 release from monocytic cell lines. *J Pharm Pharmacol* 43: 578-582.
- Tsuchiya S, Yamabe M, Yamaguchi Y et al (1980). Establishment and characterisation of a human acute monocytic leukemia cell line (THP-1). *Int J Cancer* 26 : 171-176.
- Ziegler-Heitbrock HWL, Thiel E, Futterer A et al (1988). Establishment of a human cell line (MONO MAC 6) with characteristics of mature monocytes. *Int J Cancer* 41: 456-461.

**Part 2:****List of Diploma theses, reports and/or PhDs etc. concerning the WB/IL-1 test (IPT: In vitro Pyrogen Test)**

1. Final report for the BMBF (Bundesministerium für Bildung und Forschung) (University of Konstanz, 2000). „Evaluierung und Prävalidierung eines Vollblutmodelles zum Ersatz des Pyrogentests am Kaninchen (DAB10)“, Phase I, (“Evaluation and prevalidation of a whole blood assay for the replacement of the pyrogentest with rabbits”), July 1<sup>th</sup>, 1997 – June 30<sup>th</sup>, 2000, No. 0311424
2. Final report for the BMBF (Bundesministerium für Bildung und Forschung) (Langen, Paul-Ehrlich-Institut, 2000). „Evaluierung und Prävalidierung eines Vollblutmodelles zum Ersatz des Pyrogentests am Kaninchen (DAB10)“, Phase I, (“Evaluation and prevalidation of a whole blood assay for the replacement of the pyrogentest with rabbits”), July 1<sup>th</sup>, 1997 – June 30<sup>th</sup>, 2000, No. 0311425
3. PhD-Thesis from Markus Weigandt at the Ruprecht-Karls-University of Heidelberg, institute of hygiene (Director: Prof. H.-G. Sonntag): „Der humane Vollblut-Pyrogentest: Optimierung, Validierung und Vergleich mit den Arzneibuchmethoden“ (The human whole blood pyrogen test: optimization, validation and comparison with methods regulated in the pharmacopoeias), 2000
4. Master Thesis (Master of Science: MSc), Karin Kullmann: „Adaptation des *In vitro* Pyrogen Tests (IPT) für prothetische Materialien“ (“Adaptation of the *in vitro* pyrogen test (IPT) to medical devices”), Technical University of Furtwangen, July 2002
5. Final report for the BMBF (Bundesministerium für Bildung und Forschung) (Langen, Paul-Ehrlich-Institut, 2004). „Ersatz des Pyrogentests am Kaninchen durch einen Vollbluttest“, Phase II, (“replacement of the rabbit experiment with the whole blood test”), October 1<sup>th</sup>, 2000 – September 30<sup>th</sup>, 2003, No. 0311424A
6. Final report for the BMBF (Bundesministerium für Bildung und Forschung) (University of Konstanz, 2004). „Ersatz des Pyrogentests am Kaninchen durch einen Vollbluttest“, Phase II, (“replacement of the rabbit experiment with the whole blood test”), September 1<sup>th</sup>, 2000 – August 31<sup>th</sup>, 2003, No. 0311424A

BRD: WB/IL-1

March, 2006

7. Brazil/Germany Cooperation Project: final report for the BMBF (Bundesministerium für Bildung und Forschung). „Validation of *in vitro* Cytokine Release Assay (Whole Blood Assay) for Controlling the Quality of Human Injectable Products“ for bilateral Cooperation in Science and Technology (Germany – Brazil), April 1<sup>th</sup> 2002-March 31<sup>th</sup> 2004, No. BRA 02/004
8. Cuba/Germany Cooperation Project: final report for the BMBF (Bundesministerium für Bildung und Forschung). „Pyrogenicity Testing by Human Whole Blood“ for bilateral Cooperation in Science and Technology (Germany – Cuba), January 1<sup>th</sup> , 2001- December 31<sup>th</sup> , 2003, No. CUB 00/022
9. Final report for the BMWa (Bundesministerium für Wirtschaft und Arbeit): “Entwicklung einer humanrelevanten Messtechnik für luftgetragene Toxine mit humanem Vollblut“ (development of a human relevant measurement for air-borne toxins with human whole blood), Sept 3<sup>th</sup> 2001– Sept. 30<sup>th</sup> 2003, No. KF 0317101KRF1
10. Postdoctoral lecture qualification (Habilitation), Bert Zucker, “Luftgetragene Endotoxine in Tierställen“ (“air-borne pyrogens in a stable”), Institut für Tier- und Umwelthygiene an der freien Universität Berlin, Berlin, 2004
11. Manuscript for the DIF (Deutsches Industrieforum, DIF-Fachtagung), Stefan Fennrich: “Pyrogenverunreinigungen an medizinischen Oberflächen. *In vitro* pyrogen-Test (IPT) als humanrelevantes Prüfverfahren“ (Contamination with pyrogens on medical surfaces: the *in vitro* pyrogen test (IPT) as a human specific method), Würzburg, June 21<sup>th</sup> -22<sup>th</sup> , 2004, No. DIF 21/78/FE

### Part 3: Further publications concerning the WB/IL-1 test (IPT)

1. Hartung T und Wendel A. Die Erfassung von Pyrogenen in einem humanen Vollblutmodell. ALTEX 1995,12:70-75
2. Fennrich S, Fischer M, Hartung T, Lexa P, Montag-Lessing T, Sonntag H-G, Weigandt M und Wendel A. Entwicklung und Evaluierung eines Pyrogentests mit menschlichem Blut. ALTEX 1998, 15:123-128
3. Fennrich S, Berthold S, Weigandt M, Lexa P, Sonntag H-G, Hartung T, Wendel A. Tagungsberichte, Pyrogentestung mit humanem Blut. Der Tierschutzbeauftragte 2, 1999, 102-107
4. Bonenberger J, Diekmann W, Fennrich S, Fischer M, Friedrich A, Hansper M, Hartung T, Jahnke M, Löwer J, Montag T, Petri E, Sonntag H-G, Weigand M, Wendel A, Zucker B. Pyrogentestung mit Vollblut. Zusammenfassung eines Status Workshops am Paul-Ehrlich-Institut, Langen, am 22.11.1999. Springer Verlag, Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz, 2000, 43:525-533
5. Petri E, van de Ploeg A, Habermaier B und Fennrich S. Improved detection of pyrogenic substances on polymer surfaces with an ex vivo human whole-blood assay in comparison to the Limulus amoebocyte lysate test. In: Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Editors: Balls M, van Zeller A-M, Halder M.E., Elsevier Science, 2000, 339-345

BRD: WB/IL-1

March, 2006

6. Hartung T, Fennrich S, Fischer M, Montag-Lessing T und Wendel A. Prevalidation of an Alternative to the rabbit test based on human whole blood. In: Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Editors: Balls M, van Zeller A-M, Halder M.E., Elsevier Science, 2000, 991-999
7. Fennrich S, Zucker Bert and Hartung T. Beispiel eines neuen Einsatzbereichs des humanen Vollbluttests: Entwicklung eines Messverfahrens zur Abschätzung der gesundheitlichen Gefährdung durch luftgetragene mikrobielle Verunreinigungen. ALTEX 2001, 18:41-46
8. Thomas Hartung, Ingeborg Aaberge, Susanne Berthold, Gunnar Carlin, Emmanuelle Charton, Sandra Coecke, Stefan Fennrich, Matthias Fischer, Martin Gommer, Marlies Halder, Kaare Haslov, Michael Jahnke, Thomas Montag-Lessing, Stephen Poole, Leonard Schechtman, Albrecht Wendel and Gabriele Werner-Felmayer. Novel Pyrogen Tests Based on the Human Fever Reaction, The report and Recommendations of ECVAM Workshop 43, 2001, ATLA 29, 99-123
9. Fennrich S, Atemluft, gesund oder gefährlich.....das ist hier die Frage! Tagungsberichte. ALTEX 2002, 19: 43-45
10. Hartung T. Comparison and validation of novel pyrogen tests based on the human fever reaction. ATLA 2002, 30 (Suppl. 2):49-51
11. Morath S, Stadelmaier A, Geyer A, Schmidt RR and Hartung T. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med., 2002, 195:1635-1640
12. Morath S, Geyer A, Spreitzer I, Hermann C and Hartung T. Structural decomposition and heterogeneity of commercial lipoteichoic acid preparation. Infect. Immun. 2002, 70:938-944
13. Kindinger I, Fennrich S, Zucker B, Linsel G and Hartung T. Determination of airborne pyrogens by the *in vitro* pyrogen test (IPT) based on human whole blood cytokine response. VDI-Bericht 1656 2002, 499-507
14. Schindler S, Reichstein S, Kindinger I, Hartung T, Fennrich S. New Ways in Pyrogen Testing: Replacing the Rabbit Experiment. Screening, Trends in Drug Discovery May, GIT Verlag, 2-3/2003, 4: 51-53
15. Zucker B A, Linsel G, Fennrich S, Müller W. Die Charakterisierung der entzündungsauslösenden Potenz von Bioaerosolen mittels Interleukinfreisetzung aus humanem Vollblut. Springer, VDI-Verlag. Gefahrstoffe Reinhaltung der Luft (Air Quality Control) 4, 2004, 155-158

#### 14.4 Original data

*Include all available non-transformed original data for both the proposed test method, the in vivo reference test method, and if applicable, a comparable validated test method with established performance standards.*

NOTE: The original data of the ELISA-plate reader were collected by S.Hoffman and ECVAM. These are available on the CD, which goes with the BRD.

BRD: WB/IL-1

March, 2006

#### **14.5 Performance standards**

*If appropriate performance standards for the proposed test method do not exist, performance standards for consideration by NICEATM and ICCVAM may be proposed. Examples of established performance standards can be located on the ICCVAM / NICEATM web site at <http://iccvam.niehs.nih.gov>.*



BRD: WB/IL-1

March, 2006

## APPENDIX A

**Trial plan** “Comparison And Validation Of Novel Pyrogen Tests Based On The Human Fever Reaction” Acronym: Human (e) Pyrogen Test

**Detailed protocol WB/IL-1:** “Human whole blood pyrogen test”( *electronic file name: SOP WB-IL-1*)

**Detailed protocol WB/IL-1:** *Human Whole Blood Pyrogen Test - Standard Operating Procedure for the Validation Phase*” marked with internal identifier *Sop-WBT-KNv02* (*electronic file name: SOP WB-IL-1 validation*)

**Trial plan** “Catch-up Validation of Novel Pyrogen Tests Based on the Human Fever Reaction”

**Detailed protocol 96-wells WB/IL-1:** Method 7A in *Human Whole Blood Pyrogen Test in 96-well Plates Using Fresh or Cryopreserved Blood*( *electronic file name: SOP CRYO WB IL 1*).

BRD: WB/IL-1

March, 2006

## APPENDIX B

Not all of the publications cited in the BRD (see section 12) are included as hardcopies in Appendix B, e.g. publications on statistical methods are not given.

Remark: The same set of hardcopies was included into Appendix B of all of the 5 submitted BRDs. Therefore some of the publications in Appendix B might not be referenced in the current BRD nor included in the list of the publications in section 12. Three general publications were added, which are not cited in any BRD but might be useful as background information to the validation study: the ECVAM publications on validation (Balls et al, 1995; Curren et al, 1995; Hartung et al, 2004). Several publications were included, which either give more background information on the human fever reaction or report on specific studies using *in vitro* pyrogen tests.

### *List of hard copies*

- Andrade SS, Silveira RL, Schmidt CA, Junior LB, Dalmora SL. (2003) Comparative evaluation of the human whole blood and human peripheral blood monocyte tests for pyrogens. *Int J Pharm.* Oct 20;265(1-2):115-24.
- Balls et al. (1995) Practical aspects of the validation of toxicity test procedures. ECVAM Workshop Report 5. *ATLA* 23, 129-147.
- Beutler B, Rietschel ET (2003). Innate immune sensing and its roots: the story of endotoxin. *Nature Rev Immunol.* 3: 169-176.
- Bleeker, W.K., de Groot, E.M., den Boer, P.J. et al (1994). Measurement of interleukin-6 production by monocytes for *in vitro* safety testing of hemoglobin solutions. *Artif Cells Blood Substit Immobil Biotechnol* 22: 835-840.
- Carlin G, Viitanen E. (2003) *In vitro* pyrogenicity of a multivalent vaccine: Infanrix. *PHARMEUROPA*, 15(3), 418-423.
- Curren et al (1995) The Role of prevalidation in the development, validation and acceptance of Alternative Methods. ECVAM Prevalidation Task Force Report 1. *ATLA* 23, 211-217.
- De Groote, D., Zangerle, P.F., Gevaert, Y., Fassotte, M.F., Beguin, Y., Noizat-Pirenne, F., Pirenne, J., Gathy, R., Lopez, M., Dehart I., (1992). Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. *Cytokine* 4, 239.
- Dinarelli CA, O'Connor JV, LoPreste G, Swift RL (1984). Human leukocyte pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant *Escherichia coli*. *J Clin Microbiol* 20: 323-329.
- Dinarelli CA (1999). Cytokines as endogenous pyrogens. *J Infect Dis* 179 (Suppl 2): S294-304.
- Duff GW, Atkins E (1982). The detection of endotoxin by *in vitro* production of endogenous pyrogen: comparison with amebocyte lysate gelation. *J Immunol Methods* 52: 323-331.

BRD: WB/IL-1

March, 2006

- Fennrich S, Wendel A and Hartung T. (1999). New applications of the human whole blood pyrogen assay (PyroCheck). *ALTEX* 16:146-149
- Fennrich S, Fischer M, Hartung T, Lexa P, Montag-Lessing T, Sonntag H-G, Weigandt M und Wendel A. (1999). Detection of endotoxins and other pyrogens using human whole blood. *Dev. Biol. Standards* 101:131-139
- Gaines Das et al (2004). Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis. *J. of Immunological Methods* 288, 165-177.
- Greisman SE, Hornick RB (1969). Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. *Proc Soc Exp Biol Med* 131: 1154-1158.
- Hansen, E.W. and Christensen, J.D. (1990) Comparison of cultured human mononuclear cells, Limulus amebocyte lysate and rabbits in the detection of pyrogens. *J Clin Pharm Ther.* 15: 425-433.
- Hartung T, Wendel A (1996). Detection of pyrogens using human whole blood. *In Vitro Toxicol* 9: 353-359.
- Hartung T, Aaberge I, Berthold S et al (2001). Novel pyrogen tests based on the human fever reaction. *Altern Lab Anim* 29: 99-123.
- Hartung et al (2004) A modular approach to the ECVAM principles on test validity. *ATLA* 32, 467-472.
- Hoffmann, S., Luederitz-Puechel, U., Montag-Lessing, T., Hartung, T. (2005). Optimisation of pyrogen testing in parenterals according to different pharmacopoeias by probabilistic modeling. *Journal of Endotoxin Research* 11(1): 26-31
- Hoffmann S, Peterbauer A, Schindler S, et al (2005). International validation of novel pyrogen tests based on human monocytoïd cells. *J Immunol Methods* 298: 161-173.
- Jahnke M, Weigand, Sonntag H-G. (2000). Comparative testing for pyrogens in parenteral drugs using the human whole blood pyrogen test, the rabbit in vivo pyrogen test and the LAL test. *European Journal of Parenteral Science* 5(2):39-44
- Nakagawa Y, Maeda H, Murai T. (2002) Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: comparison with a human whole blood culture test system and with the rabbit pyrogen test. *Clin Diagn Lab Immunol.* May;9(3):588-97.
- Pasare, C. and Medzhitov, R. (2003). Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. *Science* 299: 1033-1036.
- Pool EJ, Johaar G, James S, Petersen I, Bouic P. (1998) The detection of pyrogens in blood products using an ex vivo whole blood culture assay. *J Immunoassay.* May-Aug;19(2-3):95-111.
- Pool EJ, Johaar G, James S, Petersen I, Bouic P. (1999) Differentiation between endotoxin and non-endotoxin pyrogens in human albumin solutions using an ex vivo whole blood culture assay. *J Immunoassay.* Feb-May; 20(1-2):79-89.
- Poole S, Thorpe R, Meager A, Hubbard AJ, Gearing AJ (1988). Detection of pyrogen by cytokine release. *Lancet* 8577, 130.
- Poole S, Thorpe R, Meager A, Gearing AJ (1988). Assay of pyrogenic contamination in pharmaceuticals by cytokine release from monocytes. *Dev Biol Stand* 69: 121-123.

BRD: WB/IL-1

March, 2006

- Poole S, Selkirk S, Rafferty B, Meager A, Thorpe R, Gearing A (1989). Assay of pyrogenic contamination in pharmaceuticals by cytokine release. Proceedings of the European Workshop on detection and quantification of pyrogen. *Pharmeuropa special Vol 1*, November 1989: 17-18.
- Poole S, Musset MV (1989). The International Standard for Endotoxin: evaluation in an international collaborative study. *J Biol Stand* 17: 161-171.
- Poole S, Mistry Y, Ball C et al (2003). A rapid 'one-plate' in vitro test for pyrogens. *J Immunol Methods* 274: 209-220.
- Ray A, Redhead K, Selkirk S, Polle S (1991) Variability in LPS composition, antigenicity and reactivity of phase variants of *Bordetella pertussis*. *FEMS Microbiology Letters* 79, 211-218.
- Reddi, K., Nair, S.P. et al (1996). Surface-associated material from the bacterium *Actinobacillus actinomycetemcomitans* contains a peptide which, in contrast to lipopolysaccharide, directly stimulates fibroblast interleukin-6 gene transcription. *Eur. J. Biochem.* 236: 871-876.
- Schindler S, Bristow A, Cartmell T, Hartung T and Fennrich S. (2003). Comparison of the reactivity of human and rabbit blood towards pyrogenic stimuli. *ALTEX* 20:59-63.
- Schindler et al (2004) Cryopreservation of human whole blood for pyrogenicity testing. *Journal of Immunological Methods* 294, 89–100
- Schins RP, van Hartingsveldt B, Borm PJ. Ex vivo cytokine release from whole blood. A routine method for health effect screening. *Exp Toxicol Pathol.* 1996 Nov; 48(6):494-6.
- Spreitzer I, Fischer M, hartzsch K, Lüderitz-Püschel U and Montag T. (2000). Comparative Study of Rabbit Pyrogen Test and Human whole Blood Assay on Human Serum Albumin. *ALTEX* 19 (Suppl. 1):73-75
- Taktak YS, Selkirk S, Bristow AF et al (1991). Assay of pyrogens by interleukin-6 release from monocytic cell lines. *J Pharm Pharmacol* 43: 578-582.
- Tsuchiya S, Yamabe M, Yamaguchi Y et al (1980). Establishment and characterisation of a human acute monocytic leukemia cell line (THP-1). *Int J Cancer* 26 : 171-176.
- Ziegler-Heitbrock HWL, Thiel E, Futterer A et al (1988). Establishment of a human cell line (MONO MAC 6) with characteristics of mature monocytes. *Int J Cancer* 41: 456-461.

BRD: WB/IL-1

March, 2006

## APPENDIX C

### List of abbreviations and definitions

Accuracy	The ability of a test system to provide a test result close to the accepted reference value for a defined property.
BET	The bacterial endotoxin test is used to detect or quantify endotoxins of gram-negative bacterial origin using amoebocyte lysate from horseshoe crab ( <i>Limulus polyphemus</i> or <i>Tachypleus tridentatus</i> )
BRD	Background Review Document
CRYO WB/IL-1	Whole blood assay (using cryopreserved blood) with IL-1 as endpoint
CV	coefficient of variation
DL	Developing laboratory = laboratory which developed the method or the most experienced laboratory
ELC	Endotoxin limit concentration; maximum quantity of endotoxin allowed in given parenterals according to European Pharmacopoeia
Endotoxins	Endotoxins are a group of chemically similar cell-wall structures of Gram-negative bacteria, i.e. lipopolysaccharides
ELISA	Enzyme linked immunosorbent assay
EU/ml	European Units per ml
IL-1	interleukin 1
IL-6	interleukin 6
Intralaboratory reproducibility	A determination of the extent that qualified people within the same laboratory can independently and successfully replicate results using a specific protocol at different times.
Interlaboratory reproducibility	A measure of the extent to which different qualified laboratories, using the same protocol and testing the same substances, can produce qualitatively and quantitatively similar results. Inter-laboratory reproducibility is also referred to as between-laboratory reproducibility.
KN	University of Konstanz (Konstanz, Germany), developing laboratory WB/IL-1 and CRYO WB/IL-1
LPS	lipopolysaccharides
MM6	MONO MAC-6 cell line
MM6/IL-6	In vitro pyrogen test using MM6 cell line and IL-6 release

BRD: WB/IL-1

March, 2006

	as an endpoint
MVD	Maximum valid dilution; the MVD is the quotient of the ELC and the detection limit
NIBSC	National Institute for Biological Standards and Control (London, UK), developing laboratory for WB/IL-6
NL	naïve laboratory = laboratory with non or minor experience with the method
NPC	negative product control (clean, released lot of the nominated product under test)
Novartis	Novartis (Basel, Switzerland), developing laboratory PBMC/IL-6
OD	optical density
PBMC	Peripheral blood mononuclear cells
PBMC/IL-6	In vitro pyrogen test using fresh peripheral blood mononuclear cells and IL-6 release as endpoint
PBMC-CRYO/IL-6	In vitro pyrogen test using cryopreserved peripheral blood mononuclear cells and IL-6 release as endpoint
PEI	Paul-Ehrlich Institut (Langen, Germany), participating laboratory
PM	prediction model = is an explicit decision-making rule for converting the results of the in vitro method into a prediction of in vivo hazard
PPC	positive product control (product under test spiked with 0.5 EU/ml of WHO-LPS (code 94/580))
Prevalidation study	A prevalidation study is a small-scale inter-laboratory study, carried out to ensure that the protocol of a test method is sufficiently optimised and standardised for inclusion in a formal validation study. According to the ECVAM principles, the prevalidation study is divided into three phases: protocol refinement, protocol transfer and protocol performance (Curren et al, ATLA 23, 211-217).
Pyrogens	fever-causing materials
Pyrogens, endogenous	endogenous pyrogens are messenger substances released by blood cells reacting to pyrogenic materials; e.g. IL-1, IL-6, TNF- $\alpha$ , prostaglandin E <sub>2</sub>
Pyrogens, exogenous	exogenous pyrogens derive from bacteria, viruses, fungi or from the host himself
Reliability	Measures of the extent to which a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and interlaboratory

BRD: WB/IL-1

March, 2006

	reproducibility and intra-laboratory repeatability.
Relevance	Relevance of a test method describes whether it is meaningful and useful for a particular purpose. It is the extent to which the measurement result and uncertainty can accurately be interpreted as reflecting or predicting the biological effect of interest.
Repeatability	Repeatability describes the closeness of agreement between test results obtained within a single laboratory when the procedure is performed independently under repeatability conditions, i.e. in a set of conditions including the same measurement procedure, same operator, same measuring system, same operating conditions and same location, and replicated measurements over a short period of time.
RIVM	National Institute of Public Health and the Environment (Bilthoven, The Netherlands), developing laboratory MM6/IL-6 method
Sensitivity	Sensitivity is the proportion of all positive/active substances that are correctly classified by a test method.
Specificity	Specificity is proportion of all negative/inactive substances that are correctly classified by a test method.
TMB	chromogenic substrate 3,3',5,5' -tetramethylbenzidine
TNF- $\alpha$	tumour necrosis factor- $\alpha$
USP	US Pharmacopoeia
Validation	Validation is the process by which the reliability and relevance of a procedure are established for a specific purpose
Validation study	A validation study is a large-scale interlaboratory study, designed to assess the reliability and relevance of an optimised method for a particular purpose
WB/IL-1	Whole blood assay (using fresh blood) with IL-1 release as endpoint
WB/IL-6	Whole blood assay (using fresh blood) with IL-6 release as endpoint
WHO	World Health Organization